

**Gerald Bronfman Department of Oncology Annual Report 2016
Publications**

Bassam Abdulkarim

1. Ayman Oweida, **Abdulkarim B**. Ablative versus fractionated radiation therapy: A controversial role in cancer invasion and metastasis. *Oncogene*. 2016 Apr 25. doi: 10.1038/onc.2016.130. [Epub ahead of print] 2016 Nov 10;35(45):5928-5929.
2. Oweida A, Sharifi Z, Yaoxian X, Sabri S, **Abdulkarim B**. Differential Response to Ablative Ionizing Radiation in Genetically Distinct Non-Small Cell Lung Cancer Cells. *Cancer Biol Ther*. 2016 Apr 2;17(4):390-9.
3. Boychak A, Bauman G, Fisher B, **Abdulkarim B**, Amanie J, Fulton D, Murtha A, Patel S, Urtasun R, Ghosh S, Roa WH. A Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors: Late Toxicity and Quality of Life. *Am J Clin Oncol*. 2016 April. 39(2):160-6.

Jason Agulnik

1. Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, **Agulnik J**, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH; LUME-Lung 2 Study group..Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. *Lung Cancer*. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011.
2. Hoffer LJ, Robitaille L, Swinton N, **Agulnik J**, Cohen V, Small D, Pepe C, Eintracht S. Appropriate vitamin D loading regimen for patients with advanced lung cancer. *Nutr J*. 2016 Oct 6;15(1):84.
3. Kim Anh M, Kasymjanova G, Cohen V, **Agulnik J**. Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach? *Curr Oncol*. 2016 Apr;23(2):e160-1. doi: 10.3747/co.23.2955.

Hani Al-Halabi

1. Campo M, **Al-Halabi H** (Co-1st author), Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. *Oncologist*. 2016 Aug;21(8):964-73
2. Oweida A, Sharifi Z, **Halabi H**, Xu Y, Sabri S, Abdulkarim B. Differential Response to Ablative Ionizing Radiation in Genetically Distinct NonSmall Cell Lung Cancer Cells. *Cancer Biol Ther*. 2016 Apr 2;17(4):390-9

Moulay Alaoui-Jamali

1. Saad A, Bijian K, Qiu D, da Silva SD, Marques M, Chang CH, Nassour H, Ramotar D, Damaraju S, Mackey J, Bismar T, Witcher M, **Alaoui-Jamali MA**. Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2. *Sci Rep*. 2016 Nov 7;6:36699. doi: 10.1038/srep36699.
2. Nassour H, Wang Z, Saad A, Papaluca A, Brosseau N, Affar el B, **Alaoui-Jamali MA**, Ramotar D. Peroxiredoxin 1 interacts with and blocks the redox factor APE1 from activating interleukin-8 expression. *Sci Rep*. 2016 Jul 8;6:29389. doi: 10.1038/srep29389.

3. Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhadj R, Bijian K, **Alaoui-Jamali MA**, Bismar TA. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. *Mol Biol Rep*. 2016 Apr;43(4):229-40. doi: 10.1007/s11033-016-3948-4.

Thierry Alcindor

1. Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, **Alcindor T**, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, Tang S, Gao L, Kambhampati SRP, Nasroulah F, Yang L, Ramdas N, Binder P, Strevel E. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. *Annals of Oncology*. 2016 Oct 11. pii: mdw412
2. Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, **Alcindor T**, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin with or without Palifosfamide in Patients with Metastatic Soft Tissue Sarcoma. *Journal of Clinical Oncology*. 2016 Sep 12. pii: JCO676684. [Epub ahead of print]
3. *Al-Fakeeh A, Ferri L, Mulla N, Doerksen T, Al-Ruzug I, Santos F, **Alcindor T**. A Pilot Trial of FLOT Neoadjuvant Chemotherapy For Resectable Esophagogastric Adenocarcinoma. *Medical Oncology*. 2016 Jul;33(7):62. doi: 10.1007/s12032-016-0774-4. Epub 2016 May 26.
4. Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, **Alcindor T**, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcborg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase 2 trial. *Journal of Clinical Oncology*. *Journal of Clinical Oncology*. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.

Joanne Alfieri

1. Alnafisah F, **Alfieri J** (March 31, 2016) Lung Metastasis in a Case of Recurrent Poorly Differentiated Leiomyosarcoma of the Bartholin Gland: A Case Report and Review of the Literature. *Cureus* 8(3): e550. doi:10.7759/cureus.550

Raquel Aloyz

1. Pinedo-Carpio E, Davidson D, Martinez Marignac VL, Panasci J, **Aloyz R**. Adaptive metabolic rewiring to chronic SFK inhibition. *Oncotarget*. 2016 Mar 17. doi: 10.18632/oncotarget.8146. [Epub ahead of print]

Armen Aprikian

1. Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, **Aprikian A**, Chevalier S, Thomson AA. Asporin is a stromally expressed marker associated with prostate cancer progression. *Br J Cancer*. 2017 Feb 2. doi:
2. Bell MD, Brimo F, Jung S, **Aprikian AG**. Sclerosing epithelioid fibrosarcoma metastasizing to the penile shaft. *Can Urol Assoc J*. 2016 Nov-Dec;10(11-12):E398-E400. doi: 10.5489/cuaj.3528.

- Pellerin C, McKercher G, **Aprikian AG**, Saad F, Lacombe L, Carmel M, Chevalier S. A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks. *Biopreserv Biobank*. 2016 Oct;14(5):383-389.
- Klil-Drori AJ, Tascilar K, Yin H, **Aprikian A**, Bitton A, Azoulay L. Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer. *Am J Epidemiol*. 2016 Jul 1;184(1):15-22. doi: 10.1093/aje/kwv307.
- Kassouf W, **Aprikian A**, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. *Can Urol Assoc J*. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583.
- Bell MD, Yafi FA, Brimo F, Steinberg J, **Aprikian AG**, Tanguay S, Kassouf W. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. *World J Urol*. 2016 Oct;34(10):1405-9. doi: 10.1007/s00345-016-1795-5.
- Zakaria AS, Santos F, Kassouf W, Tanguay S, Aprikian A. Survival after Radical Cystectomy for Bladder Cancer in Relation to Prior Non-Muscle Invasive Disease in Quebec. *Urol Int*. 2016;97(1):49-53. doi: 10.1159/000444093.
- Sakai M, Martinez-Arguelles DB, **Aprikian AG**, Magliocco AM, Papadopoulos V. De novo steroid biosynthesis in human prostate cell lines and biopsies. *Prostate*. 2016 May;76(6):575-87. doi: 10.1002/pros.23146.
- Sanyal C, **Aprikian AG**, Cury FL, Chevalier S, Dragomir A. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis. *Cancer*. 2016 Apr 1;122(7):1085-96. doi: 10.1002/cncr.29892.
- Santos F, Dragomir A, Zakaria AS, Kassouf W, **Aprikian A**. Predictors of costs associated with radical cystectomy for bladder cancer: A population-based retrospective cohort study in the province of Quebec, Canada. *J Surg Oncol*. 2016 Feb;113(2):223-8. doi: 10.1002/jso.24132.
- Cerantola Y, Dragomir A, Tanguay S, Bladou F, **Aprikian A**, Kassouf W. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. *Urol Oncol*. 2016 Mar;34(3):119.e1-9. doi: 10.1016/j.urolonc.2015.09.010.

Jamil Asselah

- Mandilaras V, Bouganim N, Yin H, **Asselah J**, Azoulay L. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer. *Br J Cancer*. 2017 Jan 3;116(1):103-108. doi: 10.1038/bjc.2016.375
- Simoneau E, Alanazi R, Alshenaifi J, Molla N, Aljiffry M, Medkhali A, Boucher LM, **Asselah J**, Metrakos P, Hassanain M. Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. *J Surg Oncol*. 2016 Mar 9

Sarit Assouline

1. Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, Mann KK, **Assouline S**, Johnson NA, Morin RD. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. *Clin Chem*. 2016 Sep;62(9):1238-47. doi: 10.1373/clinchem.2016.255315.
2. Damlaj M, Lipton JH, **Assouline SE**. A safety evaluation of omacetaxine mepepsuccinate for the treatment of chronic myeloid leukemia. *Expert Opin Drug Saf*. 2016 Sep;15(9):1279-86. doi: 10.1080/14740338.2016.1207760.
3. Engel NW, Constantin A, Fowlkes S, **Assouline S**. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia. *J Oncol Pract*. 2016 Jun;12(6):592-4. doi: 10.1200/JOP.2016.012054. No abstract available.
4. **Assouline SE**, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Halioitis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, Oros KK, Camglioglu E, Sharma A, Christodouloupoulos R, Rousseau C, Johnson N, Crump M, Morin RD, Mann KK. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. *Blood*. 2016 Jul 14;128(2):185-94. doi: 10.1182/blood-2016-02-699520.
5. Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, **Assouline S**, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2.
6. **Assouline S**, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, Brewster M, Catalani O, Li S, McIntyre C, Sayyed P, Badoux X. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. *Lancet Haematol*. 2016 Mar;3(3):e128-38. doi: 10.1016/S2352-3026(16)00004-1.
7. Reis B, Jukofsky L, Chen G, Martinelli G, Zhong H, So WV, Dickinson MJ, Drummond M, **Assouline S**, Hashemyan M, Theron M, Blotner S, Lee JH, Kasner M, Yoon SS, Rueger R, Seiter K, Middleton SA, Kelly KR, Vey N, Yee K, Nichols G, Chen LC, Pierceall WE. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. *Haematologica*. 2016 May;101(5):e185-8. doi: 10.3324/haematol.2015.139717.
8. Morin RD, **Assouline S**, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Halioitis T, Crump M, Tosikyan A, Grande BM, MacDonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, Johnson NA. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. *Clin Cancer Res*. 2016 May 1;22(9):2290-300. doi: 10.1158/1078-0432.CCR-15-2123.
9. Andreeff M, Kelly KR, Yee K, **Assouline S**, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J,

Nichols G, Kojima K. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. *Clin Cancer Res.* 2016 Feb 15;22(4):868-76. doi: 10.1158/1078-0432.CCR-15-0481.

Laurent Azoulay

1. *Hicks BM, Yin H, Yu OH, Pollak MN, Platt RW, **Azoulay L**. GLP-1 analogues and the risk of breast cancer in patients with type 2 diabetes: population-based cohort study using the UK Clinical Practice Research Datalink. *BMJ* 2016: 355:I5340.
2. Tascilar K, **Azoulay L**, Dell'Aniello S, Bartels D, Suissa S. The use of telmisartan and the incidence of cancer. *Am J Hypertens.* 2016 Aug 24 [epub ahead of print]
3. Kamstra R, **Azoulay L**, Steele R, Klein MB, Greenaway C. Hospitalizations in immigrants and nonimmigrants diagnosed on chronic hepatitis C infection in Quebec. *Clin Infect Dis.* 2016 Dec 1;63(11):1439-1448.
4. **Azoulay L**, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Nianping H, Juurlink DN, Paterson JM, Targownik L, Turin TC, Ernst P, and the CNODES Investigators. Associations between incretin-based drugs and the risk of acute pancreatitis. *JAMA Intern Med.* 2016 Oct 1;176(10):1464-1473.
5. *Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, **Azoulay L**. Associations of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. *JAMA Intern Med* 2016 Oct 1;176(10):1474-1481
6. *Klil-Drori A, Tascilar K, Yin H, Aprikian A, Bitton A, **Azoulay L**. Androgen deprivation therapy and the incidence of inflammatory bowel disease in patients with prostate cancer. *Am J Epidemiol* 2016 Jul 1;184(1):15-22.
7. *Lian Y, Yin H, Pollak MN, Carrier S, Platt RW, Suissa S, **Azoulay L**. Phosphodiesterase-5 Inhibitors and the Risk of Melanoma and Non-Melanoma Skin Cancer: A cohort study. *Eur Urol*; 2016 Nov;70(5):808-815.
8. Filion KB, Eberg M, **Azoulay L**. Cardiovascular safety warnings and the prescribing of varenicline: An interrupted time-series analysis. *Epidemiology* 2016 Jul;27(4)e28-9.
9. **Azoulay L**, Soldera S, Yin H, Bouganim N. The use of calcium blockers and the risk of breast cancer: a population-based cohort study. *Epidemiology.* 2016 Jul;27(4):594-601.
10. *Klil-Drori A, Yin H, Tagalakis V, Aprikian A, **Azoulay L**. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. *Eur Urol* 2016 Jul;70(1):56-61.
11. *Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, **Azoulay L**. Pioglitazone use and bladder cancer risk: a population-based cohort study. *BMJ* 2016;30;352.
12. Filion KB, **Azoulay L**, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P, and the CNODES Investigators. A multi-center observational study of incretin-based drugs and the risk of heart failure. *N Engl J Med* 2016 March 24;374(12):1145-54.
13. **Azoulay L**, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik L, Turin TC, Paterson JM, Ernst P, for the CNODES Investigators. Incretin-based drugs and the risk of pancreatic cancer: an international multi-centre cohort study. *BMJ* 2016 Feb 17;352.
14. Tagalakis V Eberg M, Kahn S, **Azoulay L**. Use of statins and reduced risk of recurrence of venous thromboembolism in an older population. *Thromb Hemost.* 2016 Jan 28;115(6).

15. Simon TA, Pan X, Kawabata H, Huang HY, **Azoulay L**. The association between bleeding and the incidence of warfarin discontinuation in patients with atrial fibrillation. *Cardiovasc Ther*. 2016;34(2):94-9.
16. Wu JW, Filion KB, **Azoulay L**, Doll MK, Suissa S. The effect of long-acting insulin analogues on the risk of cancer: a systematic review of observational studies. *Diabetes Care*. 2016 39(3):486-94.
17. *Tuccori M, Filion KB, **Azoulay L**. RE: Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome. *J Natl Cancer Inst*. 2016;108(2).

Boris Bahoric

1. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, **Bahoric B**, Sultanem K, Muanza T. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. *Cureus*. 2016 Dec 9;8(12):e924. doi: 10.7759/cureus.924.

Mark Basik

1. Johnston S, **Basik M**, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti L, Mann H, Stuart M, Cristofanilli M. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. *Breast Cancer Res Treat*. 2016 Nov;160(1):91-99.
2. Légaré S, **Basik M**. Minireview: The Link Between ER α Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer. *Mol Endocrinol*. 2016 Sep;30(9):965-76. doi: 10.1210/me.2016-1072.

Gerald Batist

1. Felfoul O, Mohammadi M, Taherkhani S, de Lanauze D, Zhong Xu Y, Loghin D, Essa S, Jancik S, Houle D, Lafleur M, Gaboury L, Tabrizian M, Kaou N, Atkin M, Vuong T, **Batist G**, Beauchemin N, Radzioch D, Martel S. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. *Nat Nanotechnol*. 2016 Nov;11(11):941-947. doi: 10.1038/nnano.2016.137.
2. Bendavit G, Aboukassim T, Hilmi K, Shah S, **Batist G**. Nrf2 Transcription Factor Can Directly Regulate mTOR: LINKING CYTOPROTECTIVE GENE EXPRESSION TO A MAJOR METABOLIC REGULATOR THAT GENERATES REDOX ACTIVITY. *J Biol Chem*. 2016 Dec 2;291(49):25476-25488.
3. Paquet ER, Cui J, Davidson D, Pietrosemoli N, Hassan HH, Tsofack SP, Maltais A, Hallett MT, Delorenzi M, **Batist G**, Aloyz R, Lebel M. A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI. *J Pathol Clin Res*. 2015 Apr 9;1(3):160-72. doi: 10.1002/cjp2.17.
4. Al Moustafa AE, Al-Antary N, Aboukassim T, Akil N, **Batist G**, Yasmeen A. Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer. *Hum Vaccin Immunother*. 2016 Jul 2;12(7):1936-9. doi: 10.1080/21645515.2016.1139255.
5. McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, **Batist G**, Kavan P. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2016 Jun;15(2):135-40. doi: 10.1016/j.clcc.2015.10.003.

Nicole Beauchemin

1. Koritzinsky, M. Koch, C.A., Riley, B. **Beauchemin, N.**, Johnston, G., Johnston, M., Koropatnick, J., Loiselle, C., Maslowska, M., McCormick, C., Miller Jr, W.H., Mulligan, L. and Tsao, M.T. From Solo in the silo to Strategic Training Programs. *CBE - Life Sci. Educ.* 15, 1-3 Letter to the Editor (2016).
2. O. Felfoul, M. Mohammadi, S. Taherkhani, D. de Lanauze, L. Gaboury, N. Kaou, M. Atkin, M. Tabrizian, M. Lafleur, T. Vuong, G. Batist, **N. Beauchemin**, Radzioch, D. and S. Martel. Non-systemic delivery to tumor hypoxic regions using magneto-aerotaxis bacterial carriers. *Nature Nanotechnology*, 11(11), 941-947 (2016) doi: 10.1038/nnano.2016.137.
3. J. Chen, G. S. Raju, V. Menon, A. Majumdar, S. Kundra, J.-S. Chen, Y. J. Gi, Y. S. Jeong, L. Phan, N. A. Mistry, J. Zhang, X. Su, S. Li, S.-H. Lin, M. Javle, J. S McMurray, T. F. Rahlfs, B. Mishra, J. White, A. Rashid, **N. Beauchemin**, B. R. Weston, M. A. Shafi, J. R. Stroehlein, M. Davila, R. Akbani, J.N. Weinstein, X. Wu, and L. Mishra. Mutational profiles reveal an aberrant TGF- β -CEA regulated pathway in colon adenomas. *Plos One*, 11(4):e0153933 (2016). doi: 10.1371/journal.pone.0153933.
4. Li, N., Ngo, C.T.A., Aleynikova, O., **Beauchemin, N.** and Richard, S. The p53 status can influence the role of Sam68 in tumorigenesis. *Oncotarget* 7 (44) 71651-71659 (2016) doi: 10.18632/oncotarget.11650.
5. Wegwitz, F., Lenfert, E., Gerstel, D., von Ehrenstein, L., Einhoff, J., Schmidt, G., Logsdon, M., Brandner, J., Tiegs, G., **Beauchemin, N.**, Wagener, C., Deppert, W. and Horst, A.K. CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. *Oncotarget* 7(39):63730-63746 (2016). doi:10.18632/oncotarget.11650.
6. "The Tumor Microenvironment - Methods and Protocols". Josie Ursini-Siegel and **Nicole Beauchemin**, co-editors. *Methods in Molecular Biology*. 24 chapters. Published in September 2016. ISBN 978-1-4939-3801-8

Martin Black

1. Henry M, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, Hier M, Zeitouni A, Kost K, Mlynarek A, **Black M**, Rosberger Z, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. *Palliat Support Care*. 2016 Aug;14(4):364-75. doi: 10.1017/S1478951515001005.
2. Madana J, Morand GB, Alrasheed A, Gabra N, Laliberté F, Barona-Lleó L, Yolmo D, **Black MJ**, Sultanem K, Hier MP. Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma. *Head Neck*. 2016 Apr;38 Suppl 1:E1277-80. doi: 10.1002/hed.24210.

Manuel Borod

1. Viganò AA, Morais JA, Ciutto L, Rosenthal L, di Tomasso J, Khan S, Olders H, **Borod M**, Kilgour RD. Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. *Clin Nutr*. 2016 Sep 20. pii: S0261-5614(16)31246-8. doi: 10.1016/j.clnu.2016.09.008. [Epub ahead of print]
2. Perez J, Olivier S, Rampakakis E, **Borod M**, Shir Y. The McGill University Health Centre Cancer Pain Clinic: A Retrospective Analysis of an Interdisciplinary Approach to Cancer Pain Management. *Pain Res Manag*. 2016;2016:2157950. doi: 10.1155/2016/2157950.

Nathanial Bouganim

1. Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, **Bouganim N**, Suissa S, Azoulay L. Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Ann Oncol*. 2016 Dec 20. pii: mdw673. doi: 10.1093/annonc/mdw673.
2. Arnaout A, Kuchuk I, **Bouganim N**, Pond G, Verma S, Segal R, Dent S, Gertler S, Song X, Kanji F, Clemons M. Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study. *Curr Oncol*. 2016 Jun;23(3):e276-9. doi: 10.3747/co.23.2394.
3. Azoulay L, Soldera S, Yin H, **Bouganim N**. Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study. *Epidemiology*. 2016 Jul;27(4):594-601. doi: 10.1097/EDE.0000000000000483.
4. Jacobs C, Kuchuk I, **Bouganim N**, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. *Breast Cancer Res Treat*. 2016 Jan;155(1):77-84. doi: 10.1007/s10549-015-3646-2
5. Clemons M, **Bouganim N**, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. *JAMA Oncol*. 2016 Feb;2(2):225-31. doi: 10.1001/jamaoncol.2015.3730
6. Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, **Bouganim N**, Clemons M. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. *Support Care Cancer*. 2016 Apr;24(4):1563-9. doi: 10.1007/s00520-015-2944-x.

Pnina Brodt

1. Ham B, Fernandez MC, D'Costa Z, **Brodt P**. The diverse roles of the TNF axis in cancer progression and metastasis. *Trends Cancer Res*. 2016 Jan 1;11(1):1-27.
2. **Brodt P**. Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches. *Clin Cancer Res*. 2016 Dec 15;22(24):5971-5982. Review.
3. Fernandez MC, Rayes R, Ham B, Wang N, Bourdeau F, Milette S, Lllemann M, Bird N, Majeed A, Xu J, Kisselova T, **Brodt P**. The type I insulin-like growth factor regulates the liver stromal response to metastatic colon carcinoma cells. *Oncotarget*. 2016 Oct 12. doi: 10.18632/oncotarget.12595. [Epub ahead of print]

Robin Cohen

1. *MacKinnon CJ, Smith NG, Henry M, Milman E, Berish M, Farrace A, Körner A, Chochinov HM, **Cohen SR**. A pilot study of meaning-based group counseling for bereavement. *Omega: Journal of Death and Dying* 2016; 72(3): 210-233. doi: 10.1177/0030222815575002
2. Yamaguchi S, **Cohen SR**, Uza M. Family caregiving in Japan: the influence of cultural constructs in the care of adults with cancer. *Journal of Family Nursing* 2016; 22:392-418.

3. *Stevenson M, Achille M, Liben S, Proulx MC, Humbert N, Petti A, Macdonald ME, **Cohen SR**. Understanding how bereaved parents cope with their grief in order to inform the services provided to them. *Qualitative Health Research* 2016 DOI: 10.1177/1049732315622189
4. *O.-d'Avignon M, Dumont S, Valois P, **Cohen SR**. The needs of siblings of children with a life-threatening illness: Part 2: Psychometric validation of a measurement instrument. *Palliative and Supportive Care* 2016 DOI:10.1017/S1478951516000316
5. **Cohen SR**, Sawatzky R, Russell LB, *Shahidi J, Heyland DK, Gadermann AM. Measuring the quality of life of people at the end of life: The McGill Quality of Life Questionnaire–Revised. *Palliative Medicine* 2017. DOI:10.1177/0269216316659603

Victor Cohen

1. Hoffer LJ, Robitaille L, Swinton N, Agulnik J, **Cohen V**, Small D, Pepe C, Eintracht S. Appropriate vitamin D loading regimen for patients with advanced lung cancer. *Nutr J*. 2016 Oct 6;15(1):84.
2. Kim Anh M, Kasymjanova G, **Cohen V**, Agulnik J. Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach? *Curr Oncol*. 2016 Apr;23(2):e160-1. doi: 10.3747/co.23.2955.
3. Esfahani K, **Cohen V**. HSP90 as a novel molecular target in non-small-cell lung cancer. *Lung Cancer (Auckl)*. 2016 Mar 1;7:11-17. doi: 10.2147/LCTT.S60344. Review.

Fabio Cury

1. Loblaw A, Pickles T, Crook J, Martin AG, Vigneault E, Souhami L, **Cury F**, Morris J, Catton C, Lukka H, Cheung P, Sethukavalan P, Warner A, Yang Y, Rodrigues G; Genitourinary Radiation Oncologists of Canada (GUROC). Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. *Clin Oncol (R Coll Radiol)*. 2016 Oct 22.
2. Faria SL, Neto OB, **Cury F**, Shenouda G, Russel R, Souhami L. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes. *Can J Urol*. 2016 Apr;23(2):8209-14.
3. Sanyal C, Aprikian AG, **Cury FL**, Chevalier S, Dragomir A. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis. *Cancer*. 2016 Apr 1;122(7):1085-96.
4. Shrivastava S, Mansure JJ, Almajed W, **Cury F**, Ferbeyre G, Popovic M, Seuntjens J, Kassouf W. The Role of HMGB1 in Radioresistance of Bladder Cancer. *Mol Cancer Ther*. 2016 Mar;15(3):471-9.

François DeBlois

1. Devic S1, Mohammed H, Tomic N, Aldelaijan S, **De Blois F**, Seuntjens J, Lehnert S, Faria S. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes. *Br J Radiol*. 2016 Jun;89(1062):20150388. doi: 10.1259/bjr.20150388. Epub 2016 Mar 23.

Slobodan Devic

1. F. Di Lillo, G. Mettivier, A. Sarno, G. Tromba, N. Tomic, **S. Devic** and P. Russo, "Energy dependent calibration of XR-QA2 radiochromic film with monochromatic and polychromatic x-ray beams," *Med. Phys.* 43, 583 (2016); <http://dx.doi.org/10.1118/1.4939063>.
2. S. Aldelaijan, F. Alzorkany, B. Moftah, I. Buzurovic, J. Seuntjens, N. Tomic, **S. Devic**, "Use of a control film piece in radiochromic film dosimetry," *Physica Medica* 32, 202-207 (2016), doi: 10.1016/j.ejmp.2015.12.004.
3. P. Papaconstadopoulos, J. Seuntjens, and **S. Devic**, "Response to Comment on 'A protocol for EBT3 radiochromic film dosimetry using reflection scanning'" [*Med. Phys.* 41(12), 122101 (6pp.) (2014)]," *Med. Phys.* 43, 1580 (2016); <http://dx.doi.org/10.1118/1.4941006>.
4. **S. Devic**, N. Tomic, and D. Lewis, "Reference Radiochromic Film Dosimetry: Review of Technical Aspects," 32 (2016) 541-556.
5. **S. Devic**, H. Mohammed, N. Tomic, S. Aldelaijan, F. De Blois, J. Seuntjens, S. Lehnert, S. Faria, "FDG-PET Based Differential Uptake Volume Histograms: A Possible Approach Towards Definition of Biological Target Volumes," *Brit J Radiol* (2016), 89: 20150388.
6. **S. Devic** "Warburg Effect - a Consequence or the Cause of Carcinogenesis?" *J. Canc.* 2016; 7(7): 817-822. doi: 10.7150/jca.14274.
7. R.A. Nout, **S. Devic**, T. Niazi, J. Wyse, M. Boutros, V. Pelsser, T. Vuong, "CT-based adaptive high-dose-rate endorectal brachytherapy in the preoperative treatment of locally advanced rectal cancer: Technical and practical aspects," *Brachytherapy*, Volume 15, Issue 4, July–August 2016, Pages 477-484

Shirin Enger

1. Pater P, Bäckstöm G, Villegas F, Ahnesjö A, **Enger SA**, Seuntjens J and El Naqa Issam, Proton and light ion RBE for the induction of direct DNA double strand breaks. *Med phys*, 43(5): 2131-2141 (2016).
2. Quast U, Kaulich TW, Álvarez-Romero JT, Carlsson-Tedgren Å, **Enger SA**, Medich DC, Mourtada F, Perez-Calatayud J, Rivard MJ, Zakaria GA, A brachytherapy photon radiation quality index QBT for probe-type dosimetry. *Phys Med.* 32(6):741-8 (2016)

Michael Evans

1. **M. Evans**, R. Ruo, H. Patrocinio, E. Poon, C. Freeman, T. Hijal, W. Parker: TB - ARC : A Total Body photon ARC technique using a commercially available linac. *Med. Phys.* 43 (8) pp 4946, 2016.

Marc Fabian

1. Nishimura T, **Fabian MR**. Scanning for a unified model for translational repression by microRNAs. (2016) *EMBO J.* 35(11):1158-9.
2. Wu MK, Cotter MB, Pears J, McDermott MB, **Fabian MR**, Foulkes WD, O'Sullivan MJ.(2016) Tumor progression in DICER1-mutated cystic nephroma-witnessing the genesis of anaplastic sarcoma of the kidney. *Human Pathology* 53:114-20.
3. Wu MK, Goudie C, Druker H, Thorner P, Traubici J, Grant R, Albrecht S, Weber E, Charles A, Priest JR, **Fabian MR**, Foulkes WD. (2016) Evolution of Renal Cysts to Anaplastic Sarcoma of Kidney in a Child With DICER1 Syndrome. *Pediatric Blood Cancer* 63(7):1272-5.

4. Fouad Brahim, Mario Maira, Pablo F. Barcelona, Tahar Aboukassim, Katrina Teske, Mary-Louise Rogers, Lisa Bertram, Jing Wang, Masoud Yousefi, Robert Rush **Marc Fabian**, Neil Cashman, and H. Uri Saragovi. The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS. *PLOS One*. October 3, 2016 <http://dx.doi.org/10.1371/journal.pone.0162307>
5. MK Wu, L de Kock, L Conwell, CJR Stewart, BR King, CS Choong, K Hussain, N Sabbaghian, I MacRae, **MR Fabian**, and WD Foulkes. (2016) Functional characterization of multiple DICER1 mutations in an adolescent. *Endocrine-Related Cancer* 23(2):L1-5.

Sergio Faria

1. Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, **Faria S**, Gross CP, Yu JB. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. *Radiother Oncol*. 2016 Nov;121(2):294-298. doi: 10.1016/j.radonc.2016.10.013.
2. Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, **Faria S**, Louie AV, Owen T, Wai E, Ramchandrar K, Chan EK, Julian J, Cline K, Whelan TJ. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. *Clin Lung Cancer*. 2016 Oct 3. pii: S1525-7304(16)30224-8. doi: 10.1016/j.clcc.2016.08.002. [Epub ahead of print]
3. **Faria SL**, Neto OB, Cury F, Shenouda G, Russel R, Souhami L. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes. *Can J Urol*. 2016 Apr;23(2):8209-14.
4. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, **Faria SL**, Chen Y, Koontz BF, Paulus R, Sandler HM. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. *J Clin Oncol*. 2016 Jul 10;34(20):2325-32. doi: 10.1200/JCO.2016.67.0448.
5. Devic S, Mohammed H, Tomic N, Aldelaijan S, De Blois F, Seuntjens J, Lehnert S, **Faria S**. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes. *Br J Radiol*. 2016 Jun;89(1062):20150388. doi: 10.1259/bjr.20150388.
6. Maria OM, Maria AM, Ybarra N, Jeyaseelan K, Lee S, Perez J, Shalaby MY, Lehnert S, **Faria S**, Serban M, Seuntjens J, El Naqa I. Mesenchymal Stem Cells Adopt Lung Cell Phenotype in Normal and Radiation-induced Lung Injury Conditions. *Appl Immunohistochem Mol Morphol*. 2016 Apr;24(4):283-95. doi:

William Foulkes

1. Fahiminiya S, de Kock L, **Foulkes WD**. Biologic and Clinical Perspectives on Thyroid Cancer. *N Engl J Med*. 2016 Dec 8;375(23):2306-2307. doi: 10.1056/NEJMc1613118.

2. Witkowski L, Donini N, Byler-Dann R, Knost JA, Albrecht S, Berchuck A, McCluggage WG, Hasselblatt M, **Foulkes WD**. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases. *Fam Cancer*. 2016 Nov 19. [Epub ahead of print]
3. de Kock L, **Foulkes WD**. Sarcoma and germ-line DICER1 mutations. *Lancet Oncol*. 2016 Nov;17(11):e470. doi: 10.1016/S1470-2045(16)30522-8. No abstract available.
4. **Foulkes WD**. DNA-Repair Gene Mutations in Metastatic Prostate Cancer. *N Engl J Med*. 2016 Nov 3;375(18):1803. doi: 10.1056/NEJMc1611137.
5. Hamdi Y, Soucy P, Kuchenbaecker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caligo MA, Chiquette J, Chung WK, Claes KB, Daly MB, Damiola F, Davidson R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B; EMBRACE., Engel C, Gareth Evans D, Feliubadalo L, Foretova L, Fostira F, **Foulkes WD**, Fountzilias G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther SA; GEMO Study Collaborators., Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TV, Hart S, Hays JL; HEBON., Hogervorst FB, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Just W, Kaczmarek K, Karlan BY; KConFab Investigators., Kets CM, Kirk J, Kriege M, Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren A, Loman N, Loud JT, Manoukian S, Mariani M, Mazoyer S, McGuffog L, Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nussbaum RL, Olah E, Olopade OI, Ong KR, Oosterwijk JC, Osorio A, Papi L, Park SK, Pedersen IS, Peissel B, Segura PP, Peterlongo P, Phelan CM, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Richardson A, Robson M, Rodriguez GC, Rookus MA, Schmutzler RK, Sevenet N, Shah PD, Singer CF, Slavin TP, Snape K, Sokolowska J, Sønderstrup IM, Southey M, Spurdle AB, Stadler Z, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Tan Y, Tea MK, Teixeira MR, Teulé A, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van den Ouweland AM, van der Luijt RB, van Engelen K, van Rensburg EJ, Varon-Mateeva R, Wappenschmidt B, Wijnen JT, Rebbeck T, Chenevix-Trench G, Offit K, Couch FJ, Nord S, Easton DF, Antoniou AC, Simard J. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Res Treat*. 2017 Jan;161(1):117-134. doi: 10.1007/s10549-016-4018-2.
6. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, **Foulkes WD**, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum*

Genet. 2016 Oct 6;99(4):877-885. doi: 10.1016/j.ajhg.2016.08.016.

7. **Foulkes WD**, Sugano K. BRCA2: a grown-up cancer susceptibility gene. *Endocr Relat Cancer*. 2016 Oct;23(10):E1-3. doi: 10.1530/ERC-16-0354.
8. Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB; GEMO Study Collaborators., Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dumont M, Ehrencrona H, Ejlersen B, Ellis S; EMBRACE., Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, **Foulkes WD**, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A, Ghossaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)., Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN; KConFab Investigators.; Australian Ovarian Cancer Study Group., Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemeny LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Massuger LF, Matsuo K, Mazoyer S, McGuffog L, McLean C, McNeish I, Meindl A, Menon U, Mensenkamp AR, Milne RL, Montagna M, Moysich KB, Muir K, Mulligan AM, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Nord S, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olswold C, O'Malley D, Orlow I, Orr N, Osorio A, Park SK, Pearce CL, Pejovic T, Peterlongo P, Pfeiler G, Phelan CM, Poole EM, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Rhenius V, Rhiem K, Risch HA, Rodriguez G, Rossing MA, Rudolph A, Salvesen HB, Sangrajrang S, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Sellers TA, Seynaeve C, Shah M, Shen CY, Shu XO, Sieh W, Singer CF, Sinilnikova OM, Slager S, Song H, Soucy P, Southey MC, Stenmark-Askmal M, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tchatchou S, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, Toland AE, Tomlinson I, Torres D, Truong T, Tseng CC, Tung N, Tworoger SS, Vachon C, van den Ouweland AM, van Doorn HC, van Rensburg EJ, Van't Veer LJ, Vanderstichele A, Vergote I, Vijai J, Wang Q, Wang-Gohrke S, Weitzel JN, Wentzensen N, Whittemore AS, Wildiers H, Winqvist R, Wu AH, Yannoukakos D, Yoon SY, Yu JC, Zheng W, Zheng Y, Khanna KK, Simard J, Monteiro AN, French JD, Couch FJ, Freedman ML, Easton DF,

- Dunning AM, Pharoah PD, Edwards SL, Chenevix-Trench G, Antoniou AC, Gayther SA. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun.* 2016 Sep 7;7:12675. doi: 10.1038/ncomms12675.
9. Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, **Foulkes WD**, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *J Natl Cancer Inst.* 2016 Sep 6;109(1). pii: djw177. doi: 10.1093/jnci/djw177.
10. Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, **Foulkes WD**, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A, Hogervorst FB, Verhoef S, Carpenter J, Clarke C, Scott RJ, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Burwinkel B, Yang R, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nielsen SF, Flyger H, Benitez J, Zamora MP, Perez JI, Menéndez P, Anton-Culver H, Neuhausen S, Ziogas A, Clarke CA, Brenner H, Arndt V, Stegmaier C, Brauch H, Brüning T, Ko YD, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Antonenkova NN, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Spurdle AB, Investigators K; Australian Ovarian Cancer Study Group., Wauters E, Smeets D, Beuselinck B, Floris G, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Olson JE, Vachon C, Pankratz VS, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GG, Zheng W, Hunter DJ, Lindstrom S, Hankinson SE, Kraft P, Andrulis I, Knight JA, Glendon G, Mulligan AM, Jukkola-Vuorinen A, Grip M, Kauppila S, Devilee P, Tollenaar RA, Seynaeve C, Hollestelle A, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Eccles DM, Rafiq S, Tapper WJ, Gerty SM, Hooning MJ, Martens JW, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Brand JS, Humphreys K, Cox A, Reed MW, Luccarini C, Baynes C, Dunning AM, Hamann U, Torres D, Ulmer HU, Rüdiger T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Swerdlow A, Ashworth A, Orr N, Jones M, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Simard J, Dumont M, Soucy P, Eeles R, Muir K, Wiklund F, Gronberg H, Schleutker J, Nordestgaard BG, Weischer M, Travis RC, Neal D, Donovan JL, Hamdy FC, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Schaid DJ, Kelley JL, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Butterbach K, Park J, Kaneva R, Batra J, Teixeira MR, Kote-Jarai Z, Olama AA, Benlloch S, Renner SP, Hartmann A, Hein A, Ruebner M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Nickels S, Eilber U, Wang-Gohrke S, Odunsi K, Sucheston-Campbell LE, Friel G, Lurie G, Killeen JL, Wilkens LR, Goodman MT, Runnebaum I, Hillemanns PA, Peltari LM, Butzow R, Modugno F, Edwards RP, Ness RB, Moysich KB, du Bois A, Heitz F, Harter P, Kommoss S, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Høgdall E, Peissel B, Bonanni B, Bernard L, Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Larson MC, Fogarty ZC, Kalli KR, Liang D, Lu KH, Hildebrandt MA, Wu X, Levine DA, Dao F, Bisogna M, Berchuck A, Iversen ES,

- Marks JR, Akushevich L, Cramer DW, Schildkraut J, Terry KL, Poole EM, Stampfer M, Tworoger SS, Bandera EV, Orlov I, Olson SH, Bjorge L, Salvesen HB, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Górski B, Gronwald J, Menkiszak J, Høgdall CK, Lundvall L, Nedergaard L, Engelholm SA, Dicks E, Tyrer J, Campbell I, McNeish I, Paul J, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Cai H, Shu XO, Teten RT, Sutphen R, McLaughlin JR, Narod SA, Phelan CM, Monteiro AN, Fenstermacher D, Lin HY, Permuth JB, Sellers TA, Chen YA, Tsai YY, Chen Z, Gentry-Maharaj A, Gayther SA, Ramus SJ, Menon U, Wu AH, Pearce CL, Van Den Berg D, Pike MC, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Song H, Winship I, Chenevix-Trench G, Giles GG, Tavtigian SV, Easton DF, Milne RL. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet.* 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839.
11. Witkowski L, McCluggage WG, **Foulkes WD**. Recently characterized molecular events in uncommon gynaecological neoplasms and their clinical importance. *Histopathology.* 2016 Dec;69(6):903-913. doi: 10.1111/his.13058. Review.
 12. Castellsagué E, Rivera B, **Foulkes WD**. Colorectal Adenomas. *N Engl J Med.* 2016 Jul 28;375(4):389. doi: 10.1056/NEJMc1604867#SA3. No abstract available.
 13. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Paw Ad, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlersen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, **Foulkes WD**, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM, Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S, Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Vijai J, Karlan BY, Kast K, Investigators K, Khan S, Kwong A, Laitman Y, Lester J, Lesueur F, Liljegren A, Lubinski J, Mai PL, Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR, Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo P, Pfeiler G, Phelan CM, Piedmonte M, Poppe B, Pujana MA, Radice P, Rennert G, Rodriguez GC, Rookus MA, Ross EA, Schmutzler RK, Simard J, Singer CF, Slavin TP, Soucy P, Southey M, Steinemann D, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Szabo CI, Tea MK, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vratimos A, Weitzel JN, McGuffog L, Kirk J, Toland AE, Hamann U, Lindor N, Ramus SJ, Greene MH, Couch FJ, Offit K, Pharoah PD, Chenevix-Trench G, Antoniou AC. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS One.* 2016 Jul 27;11(7):e0158801. doi: 10.1371/journal.pone.0158801.
 14. de Kock L, Bah I, Revil T, Bérubé P, Wu MK, Sabbaghian N, Priest JR, Ragoussis J, **Foulkes WD**. Deep Sequencing Reveals Spatially Distributed Distinct Hot Spot Mutations in

- DICER1-Related Multinodular Goiter. *J Clin Endocrinol Metab.* 2016 Oct;101(10):3637-3645.
15. Larson NB, McDonnell S, Albright LC, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson J, Cussenot O, Cancel-Tassin G, Giles G, MacInnis R, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catolona WJ, **Foulkes W**, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ. Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. *Genet Epidemiol.* 2016 Sep;40(6):461-9. doi: 10.1002/gepi.21983.
 16. Stewart CJ, Charles A, **Foulkes WD**. Gynecologic Manifestations of the DICER1 Syndrome. *Surg Pathol Clin.* 2016 Jun;9(2):227-41. doi: 10.1016/j.path.2016.01.002. Review.
 17. Witkowski L, Goudie C, **Foulkes WD**, McCluggage WG. Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary): A Review with Recent Developments on Pathogenesis. *Surg Pathol Clin.* 2016 Jun;9(2):215-26. doi: 10.1016/j.path.2016.01.005. Review.
 18. de Kock L, Bah I, Brunet J, Druker H, Astigarraga I, Bosch-Barrera J, Soglio DB, Nguyen VH, Malkin D, Priest JR, **Foulkes WD**. Somatic DICER1 mutations in adult-onset pulmonary blastoma. *Eur Respir J.* 2016 Jun;47(6):1879-82. doi: 10.1183/13993003.00172-2016.
 19. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti A, Fostira F, **Foulkes WD**, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, Phelan CM, Pilarski R,

- Poppe B, Pylkäs K, Radice P, Rahman N, Rantala J, Rappaport C, Rennert G, Richardson A, Robson M, Romieu I, Rudolph A, Rutgers EJ, Sanchez MJ, Santella RM, Sawyer EJ, Schmidt DF, Schmidt MK, Schmutzler RK, Schumacher F, Scott R, Senter L, Sharma P, Simard J, Singer CF, Sinilnikova OM, Soucy P, Southey M, Steinemann D, Stenmark-Askmal M, Stoppa-Lyonnet D, Swerdlow A, Szabo CI, Tamimi R, Tapper W, Teixeira MR, Teo SH, Terry MB, Thomassen M, Thompson D, Tihomirova L, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tsimiklis H, Teulé A, Tumino R, Tung N, Turnbull C, Ursin G, van Deurzen CH, van Rensburg EJ, Varon-Mateeva R, Wang Z, Wang-Gohrke S, Weiderpass E, Weitzel JN, Whittemore A, Wildiers H, Winqvist R, Yang XR, Yannoukakos D, Yao S, Zamora MP, Zheng W, Hall P, Kraft P, Vachon C, Slager S, Chenevix-Trench G, Pharoah PD, Monteiro AA, García-Closas M, Easton DF, Antoniou AC. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nat Commun*. 2016 Apr 27;7:11375. doi: 10.1038/ncomms11375.
20. Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis AN, Sebire N, Lamovec J, Roth LM, Stewart CJ, Hasselblatt M, **Foulkes WD**, McCluggage WG. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. *Histopathology*. 2016 Nov;69(5):727-738. doi: 10.1111/his.12988.
21. Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, Sivakumaran H, Wayte N, Nones K, Waterfall JJ, Pearson J, Patch AM, Senz J, Ferreira MA, Kaurah P, Mackenzie R, Heravi-Moussavi A, Hansford S, Lannagan TR, Spurdle AB, Simpson PT, da Silva L, Lakhani SR, Clouston AD, Bettington M, Grimpen F, Busuttil RA, Di Costanzo N, Boussioutas A, Jeanjean M, Chong G, Fabre A, Olschwang S, Faulkner GJ, Bellos E, Coin L, Rioux K, Bathe OF, Wen X, Martin HC, Neklason DW, Davis SR, Walker RL, Calzone KA, Avital I, Heller T, Koh C, Pineda M, Rudloff U, Quezado M, Pichurin PN, Hulick PJ, Weissman SM, Newlin A, Rubinstein WS, Sampson JE, Hamman K, Goldgar D, Poplawski N, Phillips K, Schofield L, Armstrong J, Kiraly-Borri C, Suthers GK, Huntsman DG, **Foulkes WD**, Carneiro F, Lindor NM, Edwards SL, French JD, Waddell N, Meltzer PS, Worthley DL, Schrader KA, Chenevix-Trench G. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. *Am J Hum Genet*. 2016 May 5;98(5):830-42. doi: 10.1016/j.ajhg.2016.03.001.
22. **Foulkes WD**, Gore M, McCluggage WG. Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment. *Gynecol Oncol*. 2016 Jul;142(1):190-8. doi: 10.1016/j.ygyno.2016.04.005. Review.
23. Wu MK, Cotter MB, Pears J, McDermott MB, Fabian MR, **Foulkes WD**, O'Sullivan MJ. Tumor progression in DICER1-mutated cystic nephroma-witnessing the genesis of anaplastic sarcoma of the kidney. *Hum Pathol*. 2016 Jul;53:114-20. doi: 10.1016/j.humpath.2016.03.002.
24. Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, **Foulkes WD**, Narod SA, Akbari MR. Corrigendum: Germline RECQL mutations

- are associated with breast cancer susceptibility. *Nat Genet.* 2016 Apr;48(4):473. doi: 10.1038/ng0329-473c.
25. Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, Stewart CJ, Hendricks WP, Cunliffe H, Huntsman DG, Pautier P, Levine DA, Trent JM, Berchuck A, Hasselblatt M, **Foulkes WD**. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. *Gynecol Oncol.* 2016 Jun;141(3):454-60. doi: 10.1016/j.ygyno.2016.03.013.
 26. Wu MK, Goudie C, Druker H, Thorner P, Traubici J, Grant R, Albrecht S, Weber E, Charles A, Priest JR, Fabian MR, **Foulkes WD**. Evolution of Renal Cysts to Anaplastic Sarcoma of Kidney in a Child With DICER1 Syndrome. *Pediatr Blood Cancer.* 2016 Jul;63(7):1272-5. doi: 10.1002/pbc.25959.
 27. Sopik V, **Foulkes WD**. Risky business: getting a grip on BRIP. *J Med Genet.* 2016 May;53(5):296-7. doi: 10.1136/jmedgenet-2015-103648.
 28. Rivera B, Gayden T, Carrot-Zhang J, Nadaf J, Boshari T, Faury D, Zeinieh M, Blanc R, Burk DL, Fahiminiya S, Bareke E, Schüller U, Monoranu CM, Sträter R, Kerl K, Niederstadt T, Kurlemann G, Ellezam B, Michalak Z, Thom M, Lockhart PJ, Leventer RJ, Ohm M, MacGregor D, Jones D, Karamchandani J, Greenwood CM, Berghuis AM, Bens S, Siebert R, Zakrzewska M, Liberski PP, Zakrzewski K, Sisodiya SM, Paulus W, Albrecht S, Hasselblatt M, Jabado N, **Foulkes WD**, Majewski J. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. *Acta Neuropathol.* 2016 Jun;131(6):847-63. doi: 10.1007/s00401-016-1549-x.
 29. de Kock L, Bah I, Wu Y, Xie M, Priest JR, **Foulkes WD**. Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung. *J Thorac Oncol.* 2016 Mar;11(3):e31-3. doi: 10.1016/j.jtho.2015.09.012.
 30. Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, **Foulkes WD**, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. *Breast Cancer Res Treat.* 2016 Jan;155(2):365-73. doi: 10.1007/s10549-016-3685-3.
 31. Fahiminiya S, Witkowski L, Nadaf J, Carrot-Zhang J, Goudie C, Hasselblatt M, Johann P, Kool M, Lee RS, Gayden T, Roberts CW, Biegel JA, Jabado N, Majewski J, **Foulkes WD**. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor. *Oncotarget.* 2016 Jan 12;7(2):1732-40. doi: 10.18632/oncotarget.6459.
 32. Croce S, de Kock L, Boshari T, Hostein I, Velasco V, **Foulkes WD**, McCluggage WG. Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations. *Int J Gynecol Pathol.* 2016 Jul;35(4):301-8. doi: 10.1097/PGP.0000000000000240.
 33. Rivera B, Castellsagué E, Bah I, van Kempen LC, **Foulkes WD**. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. *N Engl J Med.* 2015 Nov 12;373(20):1985-6. doi: 10.1056/NEJMc1506878. Erratum in: *N Engl J Med.* 2015 Dec 17;373(25):e33.

34. Smith AL, Alirezaie N, Connor A, Chan-Seng-Yue M, Grant R, Selander I, Bascuñana C, Borgida A, Hall A, Whelan T, Holter S, McPherson T, Cleary S, Petersen GM, Omeroglu A, Saloustros E, McPherson J, Stein LD, **Foulkes WD**, Majewski J, Gallinger S, Zogopoulos G. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. *Cancer Lett.* 2016 Jan 28;370(2):302-12. doi: 10.1016/j.canlet.2015.10.030.
35. Pelletier S, Wong N, El Haffaf Z, **Foulkes WD**, Chiquette J, Hamet P, Simard J, Dorval M. Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. *Genet Med.* 2016 Jun;18(6):627-34. doi: 10.1038/gim.2015.135.
36. Gavino C, Hamel N, Zeng JB, Legault C, Guiot MC, Chankowsky J, Lejtenyi D, Lemire M, Alarie I, Dufresne S, Boursiquot JN, McIntosh F, Langelier M, Behr MA, Sheppard DC, **Foulkes WD**, Vinh DC. Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians. *J Allergy Clin Immunol.* 2016 Apr;137(4):1178-88.e1-7. doi: 10.1016/j.jaci.2015.09.016.
37. **Foulkes WD**, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. *Nat Rev Clin Oncol.* 2016 Jan;13(1):41-54. doi: 10.1038/nrclinonc.2015.173. Review.
38. de Kock L, Wang YC, Revil T, Badescu D, Rivera B, Sabbaghian N, Wu M, Weber E, Sandoval C, Hopman SM, Merks JH, van Hagen JM, Bouts AH, Plager DA, Ramasubramanian A, Forsmark L, Doyle KL, Toler T, Callahan J, Engelenberg C, Bouron-Dal Soglio D, Priest JR, Ragoussis J, **Foulkes WD**. High-sensitivity sequencing reveals multi-organ somatic mosaicism causing DICER1 syndrome. *J Med Genet.* 2016 Jan;53(1):43-52. doi: 10.1136/jmedgenet-2015-103428.
39. Semple J, Metcalfe KA, Lubinski J, Huzarski T, Gronwald J, Armel S, Lynch HT, Karlan B, **Foulkes W**, Singer CF, Neuhausen SL, Eng C, Iqbal J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? *Breast Cancer Res Treat.* 2015 Nov;154(1):163-9.
40. de Kock L, Boshari T, Martinelli F, Wojcik E, Niedziela M, **Foulkes WD**. Adult-Onset Cervical Embryonal Rhabdomyosarcoma and DICER1 Mutations. *J Low Genit Tract Dis.* 2016 Jan;20(1):e8-e10. doi: 10.1097/LGT.000000000000149.

Eduardo Franco

1. Tota JE, Jiang M, Ramanakumar AV, Walter SD, Kaufman JS, Coutlée F, Richardson H, Burchell AN, Koushik A, Mayrand MH, Villa LL, **Franco EL**. Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. *PLoS One.* 2016 Dec 22;11(12):e0166329. doi: 10.1371/journal.pone.0166329.
2. Coldman AJ, Gondara L, Smith LW, van Niekerk D, Ceballos K, Krajdén M, Cook D, Quinlan DJ, Lee M, Stuart GC, Peacock S, Martin RE, Gentile L, **Franco EL**, Ogilvie GS. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. *Br J Cancer.* 2016 Dec 6;115(12):1487-1494. doi: 10.1038/bjc.2016.368.
3. Kahn JA, Widdice LE, Ding L, Huang B, Brown DR, **Franco EL**, Bernstein DI. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women

- During the First 8 Years After HPV Vaccine Introduction in a Community. *Clin Infect Dis*. 2016 Nov 15;63(10):1281-1287.
4. Whittemore D, Ding L, Widdice LE, Brown DA, Bernstein DI, **Franco EL**, Kahn JA. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women. *J Womens Health (Larchmt)*. 2016 Nov;25(11):1153-1158.
 5. Smith L, van Niekerk D, Coldman A, Kraijden M, **Franco EL**, Ogilvie G. Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial. *J Obstet Gynaecol Can*. 2016 Aug;38(8):723-6. doi: 10.1016/j.jogc.2016.04.009.
 6. Rudolph SE, Lorincz A, Wheeler CM, Gravitt P, Lazcano-Ponce E, Torres-Ibarra L, León-Maldonado L, Ramírez P, Rivera B, Hernández R, **Franco EL**, Cuzick J, Méndez-Hernández P, Salmerón J; FRIDA Study Group.. Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico. *BMC Infect Dis*. 2016 Sep 1;16:461. doi: 10.1186/s12879-016-1782-x.
 7. Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, Blatter M, Moscicki AB, Harper DM, Romanowski B, Tyring SK, Ramjattan B, Schuind A, Dubin G, **Franco EL**; HPV-007 Study Group. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. *BMJ Open*. 2016 Aug 26;6(8):e011371. doi: 10.1136/bmjopen-2016-011371.
 8. Torres-Ibarra L, Lazcano-Ponce E, **Franco EL**, Cuzick J, Hernández-Ávila M, Lorincz A, Rivera B, Ramírez P, Mendiola-Pastrana I, Rudolph SE, León-Maldonado L, Hernández R, Barrios E, Gravitt P, Moscicki AB, Schmeler KM, Flores YN, Méndez-Hernández P, Salmerón J; FRIDA Study Group. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. *Salud Publica Mex*. 2016 Apr;58(2):197-210.
 9. Isidean SD, Mayrand MH, Ramanakumar AV, Gilbert L, Reid SL, Rodrigues I, Ferenczy A, Ratnam S, Coutlée F, **Franco EL**; CCCaST Study Group. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial. *Int J Cancer*. 2016 Dec 1;139(11):2456-66. doi: 10.1002/ijc.30385.
 10. Lemieux-Mellouki P, Drolet M, Brisson J, **Franco EL**, Boily MC, Baussano I, Brisson M. Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus. *Epidemiol Infect*. 2016 May;144(7):1490-9. doi: 10.1017/S0950268815002915.
 11. Madathil SA, Rousseau MC, Wynant W, Schlecht NF, Netuveli G, **Franco EL**, Nicolau B. Nonlinear association between betel quid chewing and oral cancer: Implications for prevention. *Oral Oncol*. 2016 Sep;60:25-31. doi: 10.1016/j.oraloncology.2016.06.011.
 12. Dodds L, **Franco E**. A collaboration between cousins: The Canadian Journal of Public Health and the Canadian Society for Epidemiology and Biostatistics. *Can J Public Health*. 2016 Jun 27;107(1):e1-2. doi: 10.17269/cjph.107.5460.
 13. Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Coutlée F, **Franco EL**. Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections. *J Infect Dis*. 2016 Sep 1;214(5):676-84. doi: 10.1093/infdis/jiw215.

14. Tota JE, Isidean SD, **Franco EL**. Should we lower the age for routine HPV vaccination in the United States? *Prev Med*. 2016 Aug;89:334-6. doi: 10.1016/j.ypmed.2016.05.027.
15. Laprise C, Shahul HP, Madathil SA, Thekkepurakkal AS, Castonguay G, Varghese I, Shiraz S, Allison P, Schlecht NF, Rousseau MC, **Franco EL**, Nicolau B. Periodontal diseases and risk of oral cancer in Southern India: Results from the HeNCe Life study. *Int J Cancer*. 2016 Oct 1;139(7):1512-9. doi: 10.1002/ijc.30201.
16. Laprise C, Madathil SA, Allison P, Abraham P, Raghavendran A, Shahul HP, ThekkePurakkal AS, Castonguay G, Coutlée F, Schlecht NF, Rousseau MC, **Franco EL**, Nicolau B. No role for human papillomavirus infection in oral cancers in a region in southern India. *Int J Cancer*. 2016 Feb 15;138(4):912-7. doi: 10.1002/ijc.29827.
17. Shaw E, Ramanakumar AV, El-Zein M, Silva FR, Galan L, Baggio ML, Villa LL, **Franco EL**; Ludwig-McGill Cohort Study. Reproductive and genital health and risk of cervical human papillomavirus infection: results from the Ludwig-McGill cohort study. *BMC Infect Dis*. 2016 Mar 8;16:116. doi: 10.1186/s12879-016-1446-x.
18. Ogilvie GS, Smith LW, van Niekerk D, Khurshed F, Pedersen HN, Taylor D, Thomson K, Greene SB, Babich SM, **Franco EL**, Coldman AJ. Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval. *BMC Public Health*. 2016 Mar 2;16:213. doi: 10.1186/s12889-016-2865-8.
19. Santesso N, Mustafa RA, Schünemann HJ, Arbyn M, Blumenthal PD, Cain J, Chirenje M, Denny L, De Vuyst H, Eckert LO, Forhan SE, **Franco EL**, Gage JC, Garcia F, Herrero R, Jeronimo J, Lu ER, Luciani S, Quek SC, Sankaranarayanan R, Tsu V, Broutet N; Guideline Support Group.. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. *Int J Gynaecol Obstet*. 2016 Mar;132(3):252-8. doi: 10.1016/j.ijgo.2015.07.038.
20. Sheppard CS, El-Zein M, Ramanakumar AV, Ferenczy A, **Franco EL**. Assessment of mediators of racial disparities in cervical cancer survival in the United States. *Int J Cancer*. 2016 Jun 1;138(11):2622-30. doi: 10.1002/ijc.29996.
21. El-Zein M, Richardson L, **Franco EL**. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. *J Clin Virol*. 2016 Mar;76 Suppl 1:S62-8. doi: 10.1016/j.jcv.2015.11.020. Review.

Carolyn Freeman

1. Li A, Chen X, Zhang Q, Kirsch D, Petersen I, DeLaney T, **Freeman C**, Trotti A, Hitchcock Y, Wang D. Margin reduction from IGRT for soft-tissue sarcoma: secondary analysis of RTOG 0630 results. *Practical Radiation Oncology Pract Radiat Oncol*. 2016 Jul-Aug;6(4):e135-40. doi: 10.1016/j.ppro.2015.11.012.PMID:26852173
2. Kortmann R-D, **Freeman C**, Marcus K, Claude L, Dieckmann K, Halperin E, Esiashvili N, Paulino A, Mahajan A, Seiersen K, Ahern V, Ricardi U, Carrie C. Paediatric radiation oncology in the care of childhood cancer: A position paper by the International Paediatric Radiation Oncology Society (PROS). *Radiotherapy and Oncology* 2016; 2016 May;119(2):357-60. doi: 10.1016/j.radonc.2016.03.009. Review. PMID:27106553
3. Barbosa Neto O, Garant A, Shakir S, Brossard J, Garde-Granger P, **Freeman C**. Whole Abdominal-Pelvic Radiotherapy in the Management of Primary Ewing Sarcoma of the Peritoneal Cavity. *Cureus* 2016 Jan 11;8(1):e455. doi: 10.7759/cureus.455. PMID: 26918223

4. **Freeman C**, Podgorsak E. Chapter 36. Radiation Oncology. In *The General. A history of the Montreal General Hospital*. Eds. Hanaway J, Burgess JH. McGill-Queens University Press, 2016

Vincent Giguere

1. Tahmasebi S, Jafarnejad SM, Tam IS, Gonatopoulos-Pournatzis T, Matta-Camacho E, Tsukumo Y, Yanagiya A, Li W, Atlasi Y, Caron M, Braunschweig U, Pearl D, Khoutorsky A, Gkogkas CG, Nadon R, Bourque G, Yang XJ, Tian B, Stunnenberg HG, Yamanaka Y, Blencowe BJ, **Giguère V**, Sonenberg N. Control of embryonic stem cell self-renewal and differentiation via coordinated alternative splicing and translation of YY2. *Proc Natl Acad Sci U S A*. 2016 Nov 1;113(44):12360-12367.
2. Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P, Labbé DP, Bégin LR, Tremblay ML, Park M, Bourque G, St-Pierre J, Muller WJ, **Giguère V**. ERR α mediates metabolic adaptations driving lapatinib resistance in breast cancer. *Nat Commun*. 2016 Jul 12;7:12156. doi: 10.1038/ncomms12156.
3. Yan M, Audet-Walsh É, Manteghi S, Rosa Dufour C, Walker B, Baba M, St-Pierre J, **Giguère V**, Pause A. Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1 α /ERR α . *Genes Dev*. 2016 May 1;30(9):1034-46. doi: 10.1101/gad.281410.116.
4. Audet-Walsh É, Papadopoli DJ, Gravel SP, Yee T, Bridon G, Caron M, Bourque G, **Giguère V**, St-Pierre J. The PGC-1 α /ERR α Axis Represses One-Carbon Metabolism and Promotes Sensitivity to Anti-folate Therapy in Breast Cancer. *Cell Rep*. 2016 Feb 2;14(4):920-31. doi: 10.1016/j.celrep.2015.12.086.

Philip Gordon

1. Garfinkle R, Kugler A, Pelsser V, Vasilevsky CA, Morin N, **Gordon P**, Feldman L, Boutros M. Diverticular Abscess Managed With Long-term Definitive Nonoperative Intent Is Safe. *Dis Colon Rectum*. 2016 Jul;59(7):648-55. doi: 10.1097/DCR.0000000000000624.
2. Melich G, Lim DR, Hur H, Min BS, Baik SH, Arena GO, **Gordon PH**, Kim NK. Prevention of perineal hernia after laparoscopic and robotic abdominoperineal resection: review with illustrative case series of internal hernia through pelvic mesh. *Can J Surg*. 2016 Feb;59(1):54-8. Review.
3. Al-Khamis A, Abou Khalil J, Demian M, Morin N, Vasilevsky CA, **Gordon PH**, Boutros M. Sigmoid Colectomy for Acute Diverticulitis in Immunosuppressed vs Immunocompetent Patients: Outcomes From the ACS-NSQIP Database. *Dis Colon Rectum*. 2016 Feb;59(2):101-9. doi: 10.1097/DCR.0000000000000513.

Walter Gotlieb

1. Lavoue V, **Gotlieb W**. Benefits of minimal access surgery in elderly patients with pelvic cancer. *Cancers* (2016) 12:8
2. Laskov I, Beauchamp MC, Amin O, Nader P, Amber Y, **Gotlieb WH**. Metformin Increases E-cadherin in Tumors of Diabetic Patients with Endometrial Cancer and Suppresses EMT (Epithelial-Mesenchymal-Transition) in Endometrial Cancer Cell Lines *Int J Gynecol Cancer* (2016) 26:1213-21

3. Zakhari A, Czuzoj-Shulman N, Spence AR, **Gotlieb WH**, Abenhaim HA. Hysterectomy for uterine cancer in the elderly: a comparison between laparoscopic and robotic assisted techniques. *Int J Gynecol Cancer* (2016) 26: 1222-7
4. Sun P, Wu Q, Ruan G, Zheng X, Song Y, Zhun J, Wu L, **Gotlieb WH**. Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia *Oncol Let.* 2016 Nov;12(5):3135-3142.
5. Greenwald ZR, Huang LN, Wissing, MD, Franco EL, **Gotlieb WH**. Does hormonal therapy for fertility preservation affect survival of young women with early-stage endometrial cancer?" *Cancer* (2016) Epub ahead of print
6. Hoskins P, **Gotlieb W**. Ovarian Cancer Screening. *Lancet* (2016) 387: 2602-3

Celia Greenwood

1. Sun J, Oualkacha K, Forgetta V, Zheng H-F, Richards JB, Ciampi A, **Greenwood CMT**, and UK10K Consortium. (2016). A method for analyzing multiple continuous phenotypes in rare variant association studies allowing for flexible correlations in variant effects. *European Journal of Human Genetics*, 24:(9), 1344-1351.
2. Rivera B, Gayden T, Carrot-Zhang J, Nadaf J, Boshari T, Faury D, Zeinieh M, Blanc R, Burk DL, Fahiminiya S, Bareke E, Schüller U, Monoranu CM, Sträter R, Kerl K, Niederstadt T, Kurlemann G, Ellezam B, Michalak S, Thom M, Lockhart PJ, Leventer RJ, Ohm M, MacGregor D, Jones D, Karamchandani J, **Greenwood CMT**, Berghuis AM, Bens S, Siebert R, Zakrzewska M, Liberski PP, Zakrzewski K, Sisodiya SM, Paulus W, Albrecht S, Hasselblatt M, Jabado N, Foulkes WD, Majewski J (2016). Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. *Acta Neuropathologica*, 131:6, 847-863.
3. Oualkacha K, Lakhali-Chaieb L, **Greenwood CMT**. Software Application Profile: RVPedigree: A suite of family-based rare-variant association tests for normally- and non-normally-distributed quantitative traits (2016). *International Journal of Epidemiology*, 45(2):402-7. doi: 10.1093/ije/dyw047
4. McGregor K, Bernatsky S, Colmegna I, Hudson M, Pastinen T, Labbe A, **Greenwood CMT** (2016). An evaluation of methods correcting for cell-type heterogeneity in DNA methylation studies. *Genome Biology*, 17:84. doi:10.1186/s13059-016-0935-y
5. Assouline SE, Holm Nielsen T, Chong L, Alcaide M, MacDonald D, Tosikyan A, Kezouh A, Kukreti V, Haliotis T, Froment R, **Greenwood CMT**, Klein K, Camlioglu EB, Sharma A, Miller WH, Christodouloupoulos R, Rousseau C, Johnson N, Morin RD, Mann KK. (2016). Phase II study of panobinostat +/- rituximab in relapsed diffuse large B cell lymphoma and biomarkers predictive of response. *Blood*, 128(2):185-94. doi: 10.1182/blood-2016-02-699520.
6. Turgeon M, Oualkacha K, Ciampi A, Miftah H, Dehghan G, Zanke BW, Benedet AL, Rosa-Neto P, **Greenwood CMT**, Labbe A, for the Alzheimer's Disease Neuroimaging Initiative. Principal component of explained variance: an efficient and optimal data dimension reduction framework for association studies. *Statistical Methods in Medical Research*, Epub ahead of print 2016 Jul 26. pii: 0962280216660128.
7. Oros Klein K, Oualkacha K, Lafond M-H, Bhatnagar S, Tonin PN, **Greenwood CMT**. (2016). Gene coexpression analyses differentiate networks associated with diverse cancers harbouring TP53 missense or null mutations. *Frontiers in Statistical Genetics and Methodology*, 7:137. doi: 10.3389/fgene.2016.00137.

8. Manousaki D, Kent Jr. JW, Haack K, Zhou S, Xie P, **Greenwood CM**, Brassard P, Newman DE, Cole S, Umans JG, Rouleau G, Comuzzie AG, Richards JB. (2016). Towards Precision Medicine: TBC1D4 Disruption is Common in The Inuit and Leads to Under-Diagnosis of Type 2 Diabetes. *Diabetes Care*, 39(11):1889-1895.
9. Chan D, McGraw S, Oros Klein K, Wallock LM, Konermann C, Plass C, Chan P, Robaire B, RA Jacob, **CMT Greenwood**, JM Trasler. Stability of the human sperm methylome to folic acid fortification and short-term supplementation. *Human Reproduction*, Epub ahead of print December 18, 2016.
10. van Kempen LCL, Redpath M, Elchebly M, Oros Klein K, Job B, Wilmott JS, Scolyer RA, Edqvist P-H, Pontén F, Schadendorf D, van Rijk AF, Dumay A, Helbling-Leclerc A, Michiels S, Dessen P, Lazar V, Bastian B, Wouters J, Stas M, **Greenwood CMT**, Eggermont AMM, van den Oord J, Feunteun J, Spatz A. (2016). The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. *Science Translational Medicine*. 8(369):369ra177.
11. Lakhali-Chaieb L, Oualkacha K, Richards B, **Greenwood C**. (2016). A rare variant association test in family-based designs and non-normal quantitative traits. *Statistics in Medicine*, 35(6): 905-921, doi: 10.1002/sim.6750.
12. Sun J, Bhatnagar S, Oualkacha K, Ciampi A, Greenwood C. (2016). Joint analysis of multiple blood pressure phenotypes in GAW19 data by using a multivariate rare-variant association test. *BMC Proceedings* 10 (Suppl 7): 48, <http://rdcu.be/mHth>.
13. Bhatnagar S, **Greenwood CMT**, Labbe A. (2016). Assessing transmission ratio distortion in extended families: a comparison of analysis methods. *BMC Proceedings* 10 (Suppl 7): 30, <http://rdcu.be/mHtM>.
14. **Greenwood CMT**, Xu C, Alam S, Krushkal J, Tylavsky FA, Adkins RM, Naumova AK (2016). Genetic and epigenetic variation in imprinted regions and its effect on birth. In *Epigenetics in human reproduction and development*, Editors: Anna K. Naumova & Teruko Taketo. World Scientific Publishing, Singapore.

Melissa Henry

1. Thombs BD, Benedetti A, Kloda LA, Levis B, Azar M, Riehm KE, Saadat N, Cuijpers P, Gilbody S, Ioannidis JP, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Loiselle CG, **Henry M**, Ismail Z, Mitchell N, Tonelli M. Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. *BMJ Open*. 2016 Apr 13;6(4):e011913. doi: 10.1136/bmjopen-2016-011913. Review.
2. **Henry M**, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, Rosberger Z, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. *Palliat Support Care*. 2016 Aug;14(4):364-75. doi: 10.1017/S1478951515001005.

Michael Hier

1. Jooya A, Saliba J, Blackburn A, Tamilia M, **Hier MP**, Mlynarek A, Forest VI, Rochon L, Florea A, Wang H, Payne RJ. The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules. *J Otolaryngol Head Neck Surg*. 2016 Oct 18;45(1):51.

2. Kay-Rivest E, Bouhabel S, Oughton MT, **Hier MP**. Medical Management for the Treatment of Nontuberculous Mycobacteria Infection of the Parotid Gland: Avoiding Surgery May Be Possible. *Case Rep Med*. 2016;2016:4324525. doi: 10.1155/2016/4324525.
3. Filimon S, Richardson K, **Hier MP**, Roskies M, Mlynarek AM. The use of a modified abbé island flap to reconstruct primary lip defects of over 80. *J Otolaryngol Head Neck Surg*. 2016 May 31;45(1):35. doi: 10.1186/s40463-016-0148-0.
4. Forghani R, Roskies M, Liu X, Tan X, Mlynarek A, Payne RJ, Nair JR, **Hier MP**, Levental M. Dual-Energy CT Characteristics of Parathyroid Adenomas on 25-and 55-Second 4D-CT Acquisitions: Preliminary Experience. *J Comput Assist Tomogr*. 2016 Sep-Oct;40(5):806-14. doi: 10.1097/RCT.0000000000000442.
5. Mujammami M, **Hier MP**, Payne RJ, Rochon L, Tamilya M. Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine. *Thyroid*. 2016 Jul;26(7):951-8. doi: 10.1089/thy.2016.0036.
6. Khalife S, Bouhabel S, Forest VI, **Hier MP**, Rochon L, Tamilya M, Payne RJ. The McGill Thyroid Nodule Score's (MTNS+) role in the investigation of thyroid nodules with benign ultrasound guided fine needle aspiration biopsies: a retrospective review. *J Otolaryngol Head Neck Surg*. 2016 May 4;45(1):29. doi: 10.1186/s40463-016-0141-7.
7. Roskies M, Jordan JO, Fang D, Abdallah MN, **Hier MP**, Mlynarek A, Tamimi F, Tran SD. Improving PEEK bioactivity for craniofacial reconstruction using a 3D printed scaffold embedded with mesenchymal stem cells. *J Biomater Appl*. 2016 Jul;31(1):132-9. doi: 10.1177/0885328216638636.
8. Henry M, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Black M, Rosberger Z, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. *Palliat Support Care*. 2016 Aug;14(4):364-75. doi: 10.1017/S1478951515001005.
9. Madana J, Morand GB, Alrasheed A, Gabra N, Laliberté F, Barona-Lleó L, Yolmo D, Black MJ, Sultanem K, **Hier MP**. Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma. *Head Neck*. 2016 Apr;38 Suppl 1:E1277-80. doi: 10.1002/hed.24210.

Tarek Hijal

1. G. Nader Marta, P. Poortmans, T. Buchholz and **T. Hijal**, Post-operative radiation therapy after nipple-sparing or skin-sparing mastectomy: a survey of European, North American and South American practices. *Breast J*. 2016 Sep 9. doi: 10.1111/tbj.12683. [Epub ahead of print]

Vera Hirsh

1. Langer C, **Hirsh V**, Amiri KI, Ko A, Knoble J, Johnson M, Jotte R, Mccleod M, Ong TJ, Page R, Spigel D, West HJ, Trunova N. P1.47: ABOUND.sqm QoL by Response: Interim Analysis of Squamous NSCLC Pts Treated With nab-Paclitaxel/Carboplatin Induction Therapy: Track: Advanced NSCLC. *J Thorac Oncol*. 2016 Oct;11(10S):S212-S213. doi: 10.1016/j.jtho.2016.08.069.
2. Barrios CH, Wu YL, Chih-Hsin Yang J, Sequist LV, Geater SL, Mok T, Hu CP, Yamamoto N, O'Byrne K, Lu S, **Hirsh V**, Sebastian M, Okamoto I, Shah R, Märten A, Massey D, Wind S, Schuler M. P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR

- Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC. *J Thorac Oncol.* 2016 Oct;11(10S):S210-S211. doi: 10.1016/j.jtho.2016.08.067.
- Aix SP, Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, **Hirsh V**, Chih-Hsin Yang J, Märten A, Paz-Ares L. P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC. *J Thorac Oncol.* 2016 Oct;11(10S):S203-S204. doi: 10.1016/j.jtho.2016.08.056
 - Fein L, Wu YL, Sequist LV, Geater SL, Orlov S, Lee KH, Tsai CM, Kato T, Kiura K, Barrios CH, Schuler M, **Hirsh V**, Yamamoto N, O'Byrne K, Mok T, Massey D, Märten A, Chih-Hsin Yang J. P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥ 65 Years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC. *J Thorac Oncol.* 2016 Oct;11(10S):S202-S203. doi: 10.1016/j.jtho.2016.08.055.
 - Hirsh V**, Ko A, Pilot R, Renschler MF, Socinski MA. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes. *Clin Lung Cancer.* 2016 Sep;17(5):367-374. doi: 10.1016/j.clcc.2016.04.002.
 - Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, **Hirsh V**, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol.* 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X.
 - Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, **Hirsh V**. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. *J Clin Oncol.* 2016 May 10;34(14):1676-88. doi: 10.1200/JCO.2015.63.8049. Review.
 - Schuler M, Wu YL, **Hirsh V**, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. *J Thorac Oncol.* 2016 Mar;11(3):380-90. doi: 10.1016/j.jtho.2015.11.014.

Tom Hutchinson

- Hutchinson T.A.**, Smilovitch M. Chapter 7, Experiential learning and reflection to support professionalism and professional identity formation. In: Cruess RL, Cruess SR, Steinert Y, editors. *Teaching Medical Professionalism. Supporting the Development of a Professional Identity.* 2nd ed. New York: Cambridge University Press; 2016. p. 97-112.

Arezu Jahani-Asl

- Ghaly M, Seelemann C, **Jahani-Asl A**. A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis. *J Pathol.* 2016 Dec;240(4):381-383. doi:
- Jahani-Asl A**, Cheng C, Zhang C, Bonni A. Pathogenesis of Börjeson-Forssman-Lehmann syndrome: Insights from PHF6 function. *Neurobiol Dis.* 2016 Dec;96:227-235. doi: 10.1016/j.nbd.2016.09.011. Review.
- Jahani-Asl A***, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. *Nat Neurosci*. 2016 Jun;19(6):798-806. doi: 10.1038/nn.4295.

4. Mohan S, Bonni A, **Jahani-Asl A**. Targeting OSMR in glioma stem cells. *Oncotarget*. 2017 Feb 3. doi: 10.18632/oncotarget.15066. [Epub ahead of print]

Nathalie Johnson

1. Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, **Johnson NA**, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. *PLoS Med*. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197.
2. Sesques P, **Johnson NA**. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. *Blood*. 2017 Jan 19;129(3):280-288. doi: 10.1182/blood-2016-02-636316. Review.
3. Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, Mann KK, Assouline S, **Johnson NA**, Morin RD. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. *Clin Chem*. 2016 Sep;62(9):1238-47. doi: 10.1373/clinchem.2016.255315.
4. Dupéré-Richer D, Kinal M, Pettersson F, Emond A, Calvo-Vidal MN, Nichol JN, Guilbert C, Plourde D, Klein Oros K, Nielsen TH, Ezponda T, Licht JD, **Johnson NA**, Assouline S, Cerchietti L, Miller WH Jr, Mann KK. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. *Leuk Lymphoma*. 2017 Jan;58(1):218-221. No abstract available.
5. Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Halioitis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, Oros KK, Camglioglu E, Sharma A, Christodouloupoulos R, Rousseau C, **Johnson N**, Crump M, Morin RD, Mann KK. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. *Blood*. 2016 Jul 14;128(2):185-94. doi: 10.1182/blood-2016-02-699520.
6. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, **Johnson NA**, Connors JM, Farinha P, Scott DW, Gascoyne RD. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. *Blood*. 2016 May 5;127(18):2182-8. doi: 10.1182/blood-2015-10-676700.
7. Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Halioitis T, Crump M, Tosikyan A, Grande BM, MacDonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, **Johnson NA**. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. *Clin Cancer Res*. 2016 May 1;22(9):2290-3

Petr Kavan

1. Gilabert M, Rho YS, **Kavan P**. Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. *Oncology*. 2016 Nov 12. [Epub ahead of print]

2. McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, **Kavan P**. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2016 Jun;15(2):135-40. doi: 10.1016/j.clcc.2015.10.003.

Neil Kopek

1. Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, **Kopek N**, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. *Curr Oncol*. 2016 Dec;23(6):e605-e614. doi: 10.3747/co.23.3394.
2. Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Sola AB, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, **Kopek N**, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. *Radiother Oncol*. 2016 Jan;118(1):205-8. doi: 10.1016/j.radonc.2015.12.027. No abstract available.

Antonis Koromilas

1. Zismanov V, Chichkov V, Colangelo V, Jamet S, Wang S*, Syme A, **Koromilas AE**, Crist C (2016) Phosphorylation of eIF2 α is a translational control mechanism regulating muscle stem cell quiescence and self-renewal. *Cell Stem Cell* 18:79- 90
2. Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, **Koromilas AE**, Boone DL, McGuire WP, Poklepovic A, Dent P (2016) [Permetrexed+Sorafenib] lethality is increased by inhibition of ERBB1/2/3- PI3K- NF κ B compensatory survival signaling. *Oncotarget* 26:23608- 32.
3. Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Tenkerian C*, Morita M, Balanathan P, Jean- Jean O, Stambolic V, Trost M, Furic L, Larose L, **Koromilas AE**, Asano K, Litchfield D, Larsson O, Topisirovic I (2016) "mTORC1 and CK2 coordinate ternary and eIF4F complex assembly." *Nature Communications* 7:11127
4. Rajesh K*, Krishnamoorthy JL*, Gupta J*, Kazimierczak U*, Papadakis AI, Deng Z, Wang S*, Kuninaka S, **Koromilas AE** (2016) The eIF2 α serine 51 phosphorylation- ATF4 arm promotes HIPPO signaling and cell death under oxidative stress. *Oncotarget* 7:51044- 51058.
5. Mahboubi H, **Koromilas AE**, Stochaj U (2016) AMP- kinase activation alters oxidant-induced stress granule assembly by modulating cell signaling and microtubule organization. *Molecular Pharmacology* 90:460- 8.
6. Podrzywalow- Bartnicka P, Cmoch A, Wolczyk M, Bugajski L, Tkaczyk M, Dadlez M, Nieborowska- Skorska M, **Koromilas AE**, Skorski T, Piwocka K (2016) Increased phosphorylation of eIF2 α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes. *Oncotarget* 7:79706- 79721.
7. Wang S*, Darini C*, Désaubry L, **Koromilas AE** (2016) STAT1 promotes KRAS colon tumor growth and susceptibility to pharmacological inhibition of translation initiation factor eIF4A. *Mol Cancer Ther*. 15:3055- 3063

8. Farabaugh KT, Majumder M, Guan BJ, Jobava R, Wu J, Krokowski D, Gao XH, Schuster A, Longworth M, Chan ED, Bianchi M, Dey M, **Koromilas AE**, Ramakrishnan P, Hatzoglou M (2016) PKR mediates inflammatory response induced by hyperosmotic stress. *Mol Cell Biol.* Dec 5. pii: MCB.00521- 16.
9. Goldberg AA, Nkengfac B, Sanchez AM, Moroz N, Qureshi ST, **Koromilas AE**, Wang S*, Burelle Y, Hussain SN, Kristof AS (2016) Regulation of ULK1 expression and autophagy by STAT1. *J Biol Chem.* Dec 23. pii: jbc.M116.771584. doi: 10.1074/jbc.M116.771584

Pierre Laneuville

1. Flowers CR, Costa LJ, Paquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher MA, Bence-Bruckler I, **Laneuville P**, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK. Efficacy of a pharmacokinetics-directed busulfan, cyclophosphamide and etoposide conditioning and autologous stem cell transplantation for lymphoma: Comparison of a multicenter phase 2 study and CIBMTR outcomes. *Biol Blood Marrow Transplant* 22:1197 (2016).
2. Atkins HA, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, **Laneuville P**, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS. Immunoablation with autologous hematopoietic stem cell rescue for multiple sclerosis. *Lancet* 388:576 (2016).

Susie Lau

1. Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, **Lau S**, Poveda A, González-Martín A, Muller C, Muro K, Pierce K, Suzuki M, Vermette J, Oza A. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. *Gynecol Oncol.* 2016 Jul;142(1):62-9. doi: 10.1016/j.ygyno.2016.04.019.
2. Bernardini MQ, Gien LT, **Lau S**, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). *Gynecol Oncol.* 2016 Apr;141(1):148-54. doi: 10.1016/j.ygyno.2016.02.002.

Ives Levesque

1. Papaconstadopoulos, P., **Levesque, I. R.**, Maglieri, R. and Seuntjens, J. Direct source reconstruction of clinical linear accelerators using a maximum likelihood expectation maximization algorithm in small photon fields. *Physics in Medicine and Biology* 61(3): 1078–1094 (2016).
2. Rioux, J. A., **Levesque, I. R.** and Rutt, B. K. Biexponential Longitudinal Relaxation in White Matter: Characterization and Impact on T1 Mapping with IR-FSE and MP2RAGE. *Magnetic Resonance in Medicine* 75(6):2265-77 (2016)
3. Cabana, J.-F., Gu, Y., Boudreau, M., **Levesque, I. R.**, Sled, J., Narayanan, S., Pike, B., Cohen-Adad, J. and Stikov, N. Quantitative Magnetization Transfer Imaging Made Easy with qMTLab: Software for Data Simulation, Analysis and Visualisation. *Concepts in Magnetic*

Resonance Part A, 44A(5):263–277 (2016)

4. Markel, D., **Levesque, I. R.**, Larkin, J., Léger, P. and El Naqa, I. A 4D Biomechanical Lung Phantom for Joint Segmentation/Registration Evaluation. *Physics in Medicine and Biology*, 61(19):7012-7030 (2016)
5. Ahmed Z, **Levesque IR**. Increased robustness in reference region model analysis of DCE MRI using two-step constrained approaches. *Magn Reson Med*. 2016 Oct 31. doi: 10.1002/mrm.26530. [Epub ahead of print]
6. Alonso-Ortiz E, **Levesque IR**, Paquin R, Pike GB. Field inhomogeneity correction for gradient echo myelin water fraction imaging. *Magn Reson Med*. 2016 Jul 15. doi: 10.1002/mrm.26334. [Epub ahead of print]

Sender Liberman

1. Fiore JF Jr, Castelino T, Pecorelli N, Niculiseanu P, Balvardi S, Hershorn O, **Liberman S**, Charlebois P, Stein B, Carli F, Mayo N, Feldman LS. Ensuring Early Mobilization Within an Enhanced Recovery Program for Colorectal Surgery: A Randomized Controlled Trial. *Ann Surg*. 2016 Dec 16. doi: 10.1097/SLA.0000000000002114. [Epub ahead of print]
2. Pecorelli N, Hershorn O, Baldini G, Fiore JF Jr, Stein BL, **Liberman AS**, Charlebois P, Carli F, Feldman LS. Impact of adherence to care pathway interventions on recovery following bowel resection within an established enhanced recovery program. *Surg Endosc*. 2016 Aug 18. [Epub ahead of print]
3. Minnella EM, Awasthi R, Gillis C, Fiore JF Jr, **Liberman AS**, Charlebois P, Stein B, Bousquet-Dion G, Feldman LS, Carli F. Patients with poor baseline walking capacity are most likely to improve their functional status with multimodal prehabilitation. *Surgery*. 2016 Oct;160(4):1070-9. doi: 10.1016/j.surg.2016.05.036.
4. Gillis C, Loiselle SE, Fiore JF Jr, Awasthi R, Wykes L, **Liberman AS**, Stein B, Charlebois P, Carli F. Prehabilitation with Whey Protein Supplementation on Perioperative Functional Exercise Capacity in Patients Undergoing Colorectal Resection for Cancer: A Pilot Double-Blinded Randomized Placebo-Controlled Trial. *J Acad Nutr Diet*. 2016 May;116(5):802-12. doi: 10.1016/j.jand.2015.06.007.

Carmen Loiselle

1. Koritzinsky M, Koch CA, Riley B, Beauchemin N, Johnston G, Johnston M, Koropatnick J, **Loiselle CG**, Maslowska M, McCormick C, Miller WH Jr, Mulligan L, Tsao MS. From Solo in the Silo to Strategic Training Programs. *CBE Life Sci Educ*. 2016 Spring;15(1):1e1. No abstract available.
2. Thombs BD, Benedetti A, Kloda LA, Levis B, Azar M, Riehm KE, Saadat N, Cuijpers P, Gilbody S, Ioannidis JP, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, **Loiselle CG**, Henry M, Ismail Z, Mitchell N, Tonelli M. Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. *BMJ Open*. 2016 Apr 13;6(4):e011913. doi: 10.1136/bmjopen-2016-011913. Review.
3. Wazneh LM, Tsimicalis A, **Loiselle CG**. Young Adults' Perceptions of the Venturing Out Pack Program as a Tangible Cancer Support Service. *Oncol Nurs Forum*. 2016 Jan;43(1):E34-42. doi: 10.1188/16.ONF.E34-E42. Review.

Koren Mann

1. RM Krohn, M Lemaire*, LF Negro Silva*, C Lemarié, A Bolt*, **KK Mann**, and JE Smits. High-selenium lentil diet protects against arsenic-induced atherosclerosis in a mouse model. *J Nutr Biochem.* Jan;27:9-15, 2016.
2. RD Morin#, S Assouline#, M Alcaide, A Mohajeri, RL Johnston, L Chong, J Grewal, S Yu, D Fornika, K Bushell, TH Nielsen, T Petrogiannis-Halioitis, M Crump, A Tosikyan, BM Grande, D MacDonald, C Rousseau, M Bayat, P Sesques, R Froment, M Albuquerque, Y Monczak, KK Oros, C Greenwood, Y Riazalhosseini, M Arseneault, E Camlioglu, A Constantin, Q Pan-Hammarstrom, R Peng, **KK Mann**#, and NA Johnson#. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. *Clin Cancer Res.* May 1;22(9):2290-300, 2016. #denotes equal contribution
3. AM Bolt*, MP Grant, TH Wu*, M Flores Molina, D Plourde, AD Kelly*, LF Negro Silva*, M Lemaire*, JJ Schlezinger, F Mwale, and **KK Mann**. Tungsten Promotes Sex-Specific Adipogenesis in the Bone by Altering Differentiation of Bone Marrow-Resident Mesenchymal Stromal Cells. *Toxicol Sci.* Apr;150(2):333-46, 2016.
4. SE Assouline, TH Nielsen, S Yu, M Alcaide, L Chong, D MacDonald, A Tosikyan, V Kukreti, A Kezouh, T Petrogiannis-Halioitis, M Albuquerque, D Fornika, S Alamouti, R Froment, CM Greenwood, KK Oros, E Camlioglu, A Sharma, R Christodoulopoulos, C Rousseau, N Johnson, M Crump, RD Morin, and **KK Mann**. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. *Blood.* Jul 14;128(2):185-94, 2016. Highlighted by editors and in ASH News
5. D Dupéré-Richer, M Kinal, F Pettersson, A Emond, MN Calvo-Vidal, JN Nichol, C Guilbert, D Plourde, K Klein Oros, TH Nielsen, T Ezponda, JD Licht, NA Johnson, S Assouline, L Cerchietti, WH Miller Jr, and **KK Mann**. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. *Leuk Lymphoma.* May 17:1-4, 2016.
6. M Alcaide, S Yu, K Bushell, D Fornika, JS Nielsen, BH Nelson, **KK Mann**, S Assouline, NA Johnson, and RD Morin. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. *Clin Chem.* Jul 20, 2016.
7. AM Bolt, **KK.Mann**. Tungsten: an Emerging Toxicant, Alone or in Combination. *Curr Environ Health Rep.* 2016 Dec;3(4):405-415. Review.
8. YK Young, AM Bolt, R Ahn, and **KK Mann**. "Analyzing the Tumor Microenvironment by Flow Cytometry." In *The Tumor Microenvironment: Methods and Protocols* G Ursini-Siegel and N Beauchemin Eds. 2016

Richard Margolese

1. Bear HD; Tang G; Rastogi P; Geyer CE Jr; Zoon CK; Kidwell KM; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; **Margolese RG**; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N. Soonmyung; Swain, Sandra M; Mamounas, Eleftherios P; Wolmark, Norman. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. *Annals of Surgical Oncology.* , 2016 Nov 18.
2. Ganz PA; Cecchini RS; Julian TB; **Margolese RG**; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO;

Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. *Lancet*. 387(10021):857-65, 2016 Feb 27.

3. **Margolese RG**; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. *Lancet*. 387(10021):849-56, 2016 Feb 27.

Luke McCaffrey

1. Carlis Rejon, Maia Al-Masri, and **Luke McCaffrey**. Cell Polarity Proteins in Breast Cancer Progression. *J Cell Biochem* (2016) 117:2215-2223.
2. Sudipa June Chatterjee, Ruba Halaoui, **Luke McCaffrey**. Apical–Basal Polarity as a Sensor for Epithelial Homeostasis: A Matter of Life and Death. *Curr Pathobiol Rep*. (2016) 4:99–106. Invited book chapter.

Ari Meguerditchian

1. **Meguerditchian A**, Tamblyn R, Meterissian S, Law S, Prchal J, Winslade N, Stern D. Adjuvant Endocrine Therapy in Breast Cancer: A Novel e-Health Approach in Optimizing Treatment for Seniors (OPTIMUM): A Two-Group Controlled Comparison Pilot Study. *JMIR Res Protoc*. 2016 Nov 7;5(4):e199.
2. Syrowatka A, Chang SL, Tamblyn R, Mayo NE, **Meguerditchian AN**. Psychotropic and Opioid Medication Use in Older Patients With Breast Cancer Across the Care Trajectory: A Population-Based Cohort Study. *J Natl Compr Canc Netw*. 2016 Nov;14(11):1412-1419.
3. Syrowatka A, Krömker D, **Meguerditchian AN**, Tamblyn R. Features of Computer-Based Decision Aids: Systematic Review, Thematic Synthesis, and Meta-Analyses. *J Med Internet Res*. 2016 Jan 26;18(1):e20. doi: 10.2196/jmir.4982. Review.

Sarkis Meterissian

1. Marcil G, Wong S, Trabulsi N, Allard-Coutu A, Parsyan A, Omeroglu A, Atinel G, Mesurolle B, **Meterissian S**. Fibroepithelial breast lesions diagnosed by core needle biopsy demonstrate a moderate rate of upstaging to phyllodes tumors. *Am J Surg*. 2016 Dec 27. pii: S0002-9610(16)31113-8. doi: 10.1016/j.amjsurg.2016.12.017. [Epub ahead of print]
2. Meguerditchian A, Tamblyn R, **Meterissian S**, Law S, Prchal J, Winslade N, Stern D. Adjuvant Endocrine Therapy in Breast Cancer: A Novel e-Health Approach in Optimizing Treatment for Seniors (OPTIMUM): A Two-Group Controlled Comparison Pilot Study. *JMIR Res Protoc*. 2016 Nov 7;5(4):e199.
3. Proulx F, Correa JA, Ferré R, Omeroglu A, Aldis A, **Meterissian S**, Mesurolle B. Value of pre-operative breast MRI for the size assessment of ductal carcinoma in situ. *Br J Radiol*. 2016;89(1058):20150543. doi: 10.1259/bjr.20150543.
4. Parsyan A, Moldoveanu D, Balram B, Wong S, Zhang DD, Svadzian A, Allard-Coutu A, Delisle M, Mesurolle B, **Meterissian S**. Influence of preoperative magnetic resonance imaging on the surgical management of breast cancer patients. *Am J Surg*. 2016 Jun;211(6):1089-94. doi: 10.1016/j.amjsurg.2015.08.028.

Catalin Mihalcioiu

1. Wong P, Leppert IR, Roberge D, Boudam K, Brown PD, Muanza T, Pike GB, Chankowsky J, **Mihalcioiu C**. A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. *Oncotarget*. 2016 Aug 9;7(32):50986-50996. doi: 10.18632/oncotarget.9653.

Wilson Miller

1. Nichol JN, Galbraith MD, Espinosa JM, **Miller WH Jr**. NPM and BRG1 mediate a novel mechanism of transcriptional resistance to RA in Acute Promyelocytic Leukemia. *Cell Reports*. 14(12): 2938-2949, 2016.
2. Koritzinsky M, Koch CA, Riley B, Beauchemin N, Johnston G, Johnston M, Koropatnick J, Loiselle C, Maslowska M, McCormick C, **Miller WH Jr.**, Mulligan L and Tsao MS. From solo in the silo to strategic training programs. *CBE Life Sciences Education.*; 15(1): 1e1. Doi: 10.1187/cbe.15-03-0076, 2016.
3. Dupéré-Richer D, Kinal M, Pettersson F, Emond A, Calvo-Vidal MN, Nichol JN, Guilbert C, Plourde D, Klein Oros K, Nielsen TH, Ezponda T, Licht JD, Johnson NA, Assouline S, Cerchietti L, **Miller WH Jr**, Mann KK. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. *Leuk Lymphoma*. 1-4, 2016.
4. D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, **Miller WH Jr**, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, and Wolchok JD. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. *Journal of Clinical Oncology*. DOI: 10.1200/JCO.2016.67.9258 [Epub ahead of print], 2016.

Thierry Muanza

1. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, **Muanza T**. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. *Cureus*. 2016 Dec 9;8(12):e924. doi: 10.7759/cureus.924.
2. Maria OM, Syme A, Eliopoulos N, **Muanza T**. Single-Dose Radiation-Induced Oral Mucositis Mouse Model. *Front Oncol*. 2016 Jun 27;6:154. doi: 10.3389/fonc.2016.00154.
3. Maria OM, Shalaby M, Syme A, Eliopoulos N, **Muanza T**. Adipose mesenchymal stromal cells minimize and repair radiation-induced oral mucositis. *Cytotherapy*. 2016 Sep;18(9):1129-45. doi: 10.1016/j.jcyt.2016.06.008.
4. Wong P, Leppert IR, Roberge D, Boudam K, Brown PD, **Muanza T**, Pike GB, Chankowsky J, Mihalcioiu C. A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. *Oncotarget*. 2016 Aug 9;7(32):50986-50996. doi: 10.18632/oncotarget.9653.
5. Maria OM, Kumala S, Heravi M, Syme A, Eliopoulos N, **Muanza T**. Adipose mesenchymal stromal cells response to ionizing radiation. *Cytotherapy*. 2016 Mar;18(3):384-401. doi: 10.1016/j.jcyt.2015.12.001.

Alain Nepveu

1. Kaur, S., Y. Coulombe, Z. Ramdzan, L. Leduy, J.-Y. Masson, and **A. Nepveu**. SATB1 Functions as an Accessory Factor in Base Excision Repair. *Journal of Biological Chemistry*. 2016.
2. Revandkar, A., M. L. Perciato, A. Toso, A. Alajati, J. Chen, H. Gerber, M. Dimitrov, A. Rinaldi, N. Delaleu, E. Pasquini, R. D'Antuono, S. Pinton, M. Losa, L. Gnetti, A. Arribas, P. Fraering, F. Bertoni, **A. Nepveu**, and A. Alimonti. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. *Nature Communications* 7: 13719 (12 pages). 2016.

Alexandre Orthwein

1. Fradet-Turcotte A, Sitz J, Grapton D, **Orthwein A**. BRCA2 functions: from DNA repair to replication fork stabilization. *Endocr Relat Cancer*. 2016 Oct;23(10):T1-T17. doi: 10.1530/ERC-16-0297. Review.
2. Tkáč J, Xu G, Adhikary H, Young JT, Gallo D, Escribano-Díaz C, Krietsch J, **Orthwein A**, Munro M, Sol W, Al-Hakim A, Lin ZY, Jonkers J, Borst P, Brown GW, Gingras AC, Rottenberg S, Masson JY, Durocher D. HELB Is a Feedback Inhibitor of DNA End Resection. *Mol Cell*. 2016 Feb 4;61(3):405-18. doi: 10.1016/j.molcel.2015.12.013.

Lawrence Panasci

1. Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, Nanni O, Miller WH Jr, **Panasci LC**. Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. *PLoS One*. 2016 Dec 19;11(12):e0167906. doi: 10.1371/journal.pone.0167906.
2. Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, **Panasci L**, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. *Lancet*. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3.
3. Almajed MM, Esfahani K, Pelmus M, **Panasci L**. Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy. *BMJ Case Rep*. 2016 Jun 2;2016. pii: bcr2016215525. doi: 10.1136/bcr-2016-215525.
4. McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, **Panasci L**, Melnychuk D, Batist G, Kavan P. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2016 Jun;15(2):135-40. doi: 10.1016/j.clcc.2015.10.003.

Valerie Panet-Raymond

1. Shenouda G, Souhami L, Petrecca K, Owen S, **Panet-Raymond V**, Guiot MC, Corredor AG, Abdulkarim B. A Phase 2 of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Therapy with Concurrent and Adjuvant Temozolomide for Patients with Glioblastoma (2017). *Int J Radiat Oncol Biol Phys*. Marc 1; 97(3): 487-494.
2. Bauman G, Yartsev S, Roberge D, MacRae R, Roa W, **Panet-Raymond V**, Masucci L, Yaremko B, D'souza D, Palma D, Sexton T, Yu E, Pantorotto JR, Ahmad B, Fisher B, Dar

AR, Lambert C, Pond G, Stitt L, Tay KY, Rodrigues G. (2016) *J Neurooncol.* 128(3):431-6.

Morag Park

1. Jandaghi P, Najafabadi HS, Bauer AS, Papadakis AI, Fassan M, Hall A, Monast A, von Knebel Doeberitz M, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Sipos B, Auld D, Lathrop M, **Park M**, Büchler MW, Strobel O, Hackert T, Giese NA, Zogopoulos G, Sangwan V, Huang S, Riazalhosseini Y, Hoheisel JD. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. *Gastroenterology.* 2016 Dec;151(6):1218-1231. doi: 10.1053/j.gastro.2016.08.040.
2. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, **Park M**, Jones P, Hortobagyi GN, Hung MC. Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. *Nat Med.* 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192c.
3. Rajadurai CV, Havrylov S, Coelho PP, Ratcliffe CD, Zaoui K, Huang BH, Monast A, Chughtai N, Sangwan V, Gertler FB, Siegel PM, **Park M**. 5'-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. *J Cell Biol.* 2016 Sep 12;214(6):719-34. doi: 10.1083/jcb.201501003.
4. Bertos NR, **Park M**. Laser Capture Microdissection as a Tool to Study Tumor Stroma. *Methods Mol Biol.* 2016;1458:13-25. doi: 10.1007/978-1-4939-3801-8_2.
5. Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P, Labbé DP, Bégin LR, Tremblay ML, **Park M**, Bourque G, St-Pierre J, Muller WJ, Giguère V. ERR α mediates metabolic adaptations driving lapatinib resistance in breast cancer. *Nat Commun.* 2016 Jul 12;7:12156. doi: 10.1038/ncomms12156.
6. Ratcliffe CD, Sahgal P, Parachoniak CA, Ivaska J, **Park M**. Regulation of Cell Migration and β 1 Integrin Trafficking by the Endosomal Adaptor GGA3. *Traffic.* 2016 Jun;17(6):670-88. doi: 10.1111/tra.12390.
7. Boulay PL, Mitchell L, Turpin J, Huot-Marchand JÉ, Lavoie C, Sanguin-Gendreau V, Jones L, Mitra S, Livingstone JM, Campbell S, Hallett M, Mills GB, **Park M**, Chodosh L, Strathdee D, Norman JC, Muller WJ. Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. *Cancer Res.* 2016 May 1;76(9):2662-74. doi: 10.1158/0008-5472.CAN-15-2782.
8. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, **Park M**, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. *Nat Med.* 2016 Feb;22(2):194-201. doi: 10.1038/nm.4032.

William Parker

1. **Parker W**. CAMPEP Residencies in a Canadian Context: Comprehensive Cancer Centers and Integrated Learning Environments. *Med Phys.* 2016 Jun;43(6):3808. doi: 10.1118/1.4957804.
2. M. Evans, R. Ruo, H. Patrocínio, E. Poon, C. Freeman, T. Hijal, **W. Parker**. TB - ARC: A Total Body photon ARC technique using a commercially available linac. *Med. Phys.* 43 (8) pp 4946, 2016.

Jerry Pelletier

1. Steinberger J, Chu J, Maïga RI, Sleiman K, **Pelletier J**. Developing anti-neoplastic biotherapeutics against eIF4F. *Cell Mol Life Sci*. 2016 Dec 21. doi: 10.1007/s00018-016-2430-8. [Epub ahead of print] Review.
2. Katigbak A, Cencic R, Robert F, Sénécha P, Scuoppo C, **Pelletier J**. A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors. *Sci Rep*. 2016 Dec 16;6:38968. doi: 10.1038/srep38968.
3. Chu J, Cargnello M, Topisirovic I, **Pelletier J**. Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer. *Trends Cell Biol*. 2016 Dec;26(12):918-933. doi: 10.1016/j.tcb.2016.06.005. Review.
4. Cencic R, **Pelletier J**. Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A. *Translation (Austin)*. 2016 Jan 4;4(1):e1137381. doi: 10.1080/21690731.2015.1137381. Review.
5. Chu J, Galicia-Vázquez G, Cencic R, Mills JR, Katigbak A, Porco JA Jr, **Pelletier J**. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A. *Cell Rep*. 2016 Jun 14;15(11):2340-7. doi: 10.1016/j.celrep.2016.05.005.
6. Wang W, Cencic R, Whitesell L, **Pelletier J**, Porco JA Jr. Synthesis of Aza-Rocaglates via ES IPT-Mediated (3+2) Photocycloaddition. *Chemistry*. 2016 Aug 16;22(34):12006-10. doi: 10.1002/chem.201602953.
7. Henry S, Kidner R, Reisenauer MR, Magedov IV, Kiss R, Mathieu V, Lefranc F, Dasari R, Evidente A, Yu X, Ma X, Pertsemlidis A, Cencic R, **Pelletier J**, Cavazos DA, Brenner AJ, Aksenov AV, Rogelj S, Kornienko A, Frolova LV. 5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells. *Eur J Med Chem*. 2016 Sep 14;120:313-28. doi: 10.1016/j.ejmech.2016.05.004.
8. Manteghi S, Gingras MC, Kharitidi D, Galarneau L, Marques M, Yan M, Cencic R, Robert F, Paquet M, Witcher M, **Pelletier J**, Pause A. Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer. *Cell Rep*. 2016 May 31;15(9):1893-900. doi: 10.1016/j.celrep.2016.04.076.
9. Bohne F, Langer D, Martiné U, Eider CS, Cencic R, Begemann M, Elbracht M, Bülow L, Eggermann T, Zechner U, **Pelletier J**, Zabel BU, Enklaar T, Prawitt D. Kaiso mediates human ICR1 methylation maintenance and H19 transcriptional fine regulation. *Clin Epigenetics*. 2016 May 4;8:47. doi: 10.1186/s13148-016-0215-4.
10. Lee T, **Pelletier J**. The biology of DHX9 and its potential as a therapeutic target. *Oncotarget*. 2016 Jul 5;7(27):42716-42739. doi: 10.18632/oncotarget.8446. Review.
11. Gandin V, Masvidal L, Hulea L, Gravel SP, Cargnello M, McLaughlan S, Cai Y, Balanathan P, Morita M, Rajakumar A, Furic L, Pollak M, Porco JA Jr, St-Pierre J, **Pelletier J**, Larsson O, Topisirovic I. nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. *Genome Res*. 2016 May;26(5):636-48. doi: 10.1101/gr.197566.115.
12. Malina A, Cameron CJ, Robert F, Blanchette M, Dostie J, **Pelletier J**. PAM multiplicity marks genomic target sites as inhibitory to CRISPR-Cas9 editing. *Nat Commun*. 2015 Dec 8;6:10124. doi: 10.1038/ncomms10124.

13. Chu J, Cencic R, Wang W, Porco JA Jr, **Pelletier J**. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status. *Mol Cancer Ther*. 2016 Jan;15(1):136-41. doi: 10.1158/1535-7163.MCT-15-0409.

Alan Peterson

1. Groh J, Friedman HC, Orel N, Ip CW, Fischer S, Spahn I, Schäffner E, Hörner M, Stadler D, Buttman M, Varallyay C, Solymosi L, Sendtner M, **Peterson AC**, Martini R. Pathogenic inflammation in the CNS of mice carrying human PLP1 mutations. *Hum Mol Genet*. 2016 Aug 29. pii: ddw296. [Epub ahead of print] PMID: 27577873
2. Chattopadhyay A, Pinkaew D, Doan HQ, Jacob RB, Verma SK, Friedman H, **Peterson AC**, Kuyumcu-Martinez MN, McDougal OM, Fujise K. Fortilin potentiates the peroxidase activity of Peroxiredoxin-1 and protects against alcohol-induced liver damage in mice. *Sci Rep*. 2016 Jan 4;6:18701. doi: 10.1038/srep18701. PMID:26726832
3. Dionne N, Dib S, Finsen B, Denarier E, Kuhlmann T, Drouin R, Kokoeva M, Hudson TJ, Siminovitch K, Friedman HC, **Peterson AC**. Functional organization of an Mbp enhancer exposes striking transcriptional regulatory diversity within myelinating glia. *Glia*. 2016 Jan;64(1):175-94. doi: 10.1002/glia. 22923. PMID:26507463
4. **Peterson A**. CRISPR: express delivery to any DNA address. *Oral Dis*. 17 May 2016:5-11. doi: 10.1111/odi.12487. PMID: 27040868

Michael Pollak

1. Murphy N, Falk RT, Messinger DB, **Pollak M**, Xue X, Lin J, Sgueglia R, Strickler HD, Gaudet MM, Gunter MJ. Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. *PLoS One*. 2016 Dec 8;11(12):e0167832. doi: 10.1371/journal.pone.0167832.
2. Kaplan RC, Strizich G, Aneke-Nash C, Dominguez-Islas C, Bůžková P, Strickler H, Rohan T, **Pollak M**, Kuller L, Kizer JR, Cappola A, Li CI, Psaty BM, Newman A. Insulinlike growth factor binding protein-1 and ghrelin predict health outcomes among older adults: CHS cohort. *J Clin Endocrinol Metab*. 2016 Nov 7:jc20162779. [Epub ahead of print]
3. Hicks BM, Yin H, Yu OH, **Pollak MN**, Platt RW, Azoulay L. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. *BMJ*. 2016 Oct 20;355:i5340. doi: 10.1136/bmj.i5340.
4. Babic A, Bao Y, Qian ZR, Yuan C, Giovannucci EL, Aschard H, Kraft P, Amundadottir LT, Stolzenberg-Solomon R, Morales-Oyarvide V, Ng K, Stampfer MJ, Ogino S, Buring JE, Sesso HD, Gaziano JM, Rifai N, **Pollak MN**, Anderson ML, Cochrane BB, Luo J, Manson JE, Fuchs CS, Wolpin BM. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. *Cancer Res*. 2016 Dec 15;76(24):7160-7167.
5. Choi J, Lee JH, Koh I, Shim JK, Park J, Jeon JY, Yun M, Kim SH, Yook JI, Kim EH, Chang JH, Kim SH, Huh YM, Lee SJ, **Pollak M**, Kim P, Kang SG, Cheong JH. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). *Oncotarget*. 2016 Oct 4;7(40):65643-65659. doi: 10.18632/oncotarget.11595.

6. Gusscott S, Jenkins CE, Lam SH, Giambra V, **Pollak M**, Weng AP. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. *PLoS One*. 2016 Aug 17;11(8):e0161158. doi: 10.1371/journal.pone.0161158.
7. Bhat M, Yanagiya A, Graber T, Razumilava N, Bronk S, Zammit D, Zhao Y, Zakaria C, Metrakos P, **Pollak M**, Sonenberg N, Gores G, Jaramillo M, Morita M, Alain T. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. *Oncotarget*. 2016 Jul 18. doi: 10.18632/oncotarget.10671. [Epub ahead of print]
8. Hayes BD, Brady L, **Pollak M**, Finn SP. Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. *Cancer Epidemiol Biomarkers Prev*. 2016 Sep;25(9):1281-8. doi: 10.1158/1055-9965.EPI-16-0223. Review.
9. Teumer A, Qi Q, Nethander M, Aschard H, Bandinelli S, Beekman M, Berndt SI, Bidlingmaier M, Broer L; CHARGE Longevity Working Group., Cappola A, Ceda GP, Chanock S, Chen MH, Chen TC, Chen YD, Chung J, Del Greco Miglianico F, Eriksson J, Ferrucci L, Friedrich N, Gnewuch C, Goodarzi MO, Grarup N, Guo T, Hammer E, Hayes RB, Hicks AA, Hofman A, Houwing-Duistermaat JJ, Hu F, Hunter DJ, Husemoen LL, Isaacs A, Jacobs KB, Janssen JA, Jansson JO, Jehmlich N, Johnson S, Juul A, Karlsson M, Kilpelainen TO, Kovacs P, Kraft P, Li C, Linneberg A, Liu Y, Loos RJ; Body Composition Genetics Consortium., Lorentzon M, Lu Y, Maggio M, Magi R, Meigs J, Mellström D, Nauck M, Newman AB, **Pollak MN**, Pramstaller PP, Prokopenko I, Psaty BM, Reincke M, Rimm EB, Rotter JJ, Saint Pierre A, Schurmann C, Seshadri S, Sjögren K, Slagboom PE, Strickler HD, Stumvoll M, Suh Y, Sun Q, Zhang C, Svensson J, Tanaka T, Tare A, Tönjes A, Uh HW, van Duijn CM, van Heemst D, Vandenput L, Vasani RS, Völker U, Willems SM, Ohlsson C, Wallaschofski H, Kaplan RC. Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits. *Aging Cell*. 2016 Oct;15(5):811-24. doi: 10.1111/acel.12490.
10. Lian Y, Yin H, **Pollak MN**, Carrier S, Platt RW, Suissa S, Azoulay L. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. *Eur Urol*. 2016 Nov;70(5):808-815. doi: 10.1016/j.eururo.2016.04.035.
11. Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, **Pollak MN**. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. *Breast Cancer Res Treat*. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z.
12. Chandel NS, Avizonis D, Reczek CR, Weinberg SE, Menz S, Neuhaus R, Christian S, Haegebarth A, Algire C, **Pollak M**. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? *Cell Metab*. 2016 Apr 12;23(4):569-70. doi: 10.1016/j.cmet.2016.03.010.
13. Gandin V, Masvidal L, Hulea L, Gravel SP, Cargnello M, McLaughlan S, Cai Y, Balanathan P, Morita M, Rajakumar A, Furic L, **Pollak M**, Porco JA Jr, St-Pierre J, Pelletier J, Larsson O, Topisirovic I. nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. *Genome Res*. 2016 May;26(5):636-48. doi: 10.1101/gr.197566.115.
14. Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, **Pollak M**, Zi X. High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ~240-Fold Higher Drug

- Concentration in Urine than Serum. *Mol Cancer Ther.* 2016 Mar;15(3):430-8. doi: 10.1158/1535-7163.MCT-15-0714-T.
15. Hofmann JN, Birmann BM, Teras LR, Pfeiffer RM, Wang Y, Albanes D, Baris D, Colditz GA, De Roos AJ, Giles GG, Hosgood HD, Lan Q, Landgren O, Liao LM, Rothman N, Weinstein SJ, **Pollak MN**, Neuhouser ML, Purdue MP. Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. *Cancer Res.* 2016 Apr 1;76(7):1935-41. doi: 10.1158/0008-5472.CAN-15-2406.
 16. Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JA, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, **Pollak MN**, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. *Cancer Res.* 2016 Apr 15;76(8):2288-300. doi: 10.1158/0008-5472.CAN-15-1551.
 17. Horne HN, Sherman ME, Pfeiffer RM, Figueroa JD, Khodr ZG, Falk RT, **Pollak M**, Patel DA, Palakal MM, Linville L, Papathomas D, Geller B, Vacek PM, Weaver DL, Chicoine R, Shepherd J, Mahmoudzadeh AP, Wang J, Fan B, Malkov S, Herschorn S, Hewitt SM, Brinton LA, Gierach GL. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. *Breast Cancer Res.* 2016 Feb 18;18(1):24. doi: 10.1186/s13058-016-0678-4.
 18. Aneke-Nash CS, Dominguez-Islas C, Bůžková P, Qi Q, Xue X, **Pollak M**, Strickler HD, Kaplan RC. Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. *Growth Horm IGF Res.* 2016 Feb;26:11-6. doi: 10.1016/j.ghir.2015.12.007.
 19. Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, **Pollak M**. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. *Breast Cancer Res.* 2016 Jan 4;18(1):1. doi: 10.1186/s13058-015-0660-6.
 20. Iyengar NM, Zhou XK, Gucalp A, Morris PG, Howe LR, Giri DD, Morrow M, Wang H, **Pollak M**, Jones LW, Hudis CA, Dannenberg AJ. Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. *Clin Cancer Res.* 2016 May 1;22(9):2283-9. doi: 10.1158/1078-0432.CCR-15-2239.

Stéphane Richard

1. Neault M, F.A. Mallette and **S. Richard**. 2016. miR-137 modulates a tumour suppressor network inducing senescence in pancreatic cancer cells. *Cell Reports* 14:1966-78
2. Blanc RS, G. Vogel, C. Crist and **S. Richard**. 2016. PRMT7 preserves satellite cell regeneration capacity. *Cell Reports* 14:1528-39
3. *Darbelli, L, G. Vogel, G. Almazan and **S. Richard**. 2016. Quaking regulates neurofascin 155 expression for myelin and axoglial junction maintenance. *J Neurosci* 36:4106-20

4. Li, N, CT Ngo, O. Aleynikova, N. Beauchemin, and **S. Richard**. 2016. The p53 status can influence the role of Sam68 in tumorigenesis. *Oncotarget*. Sept 28. Doi:10.18632/oncotarget.12305

Zeev Rosberger

1. Perez S, Tatar O, Shapiro GK, Dubé E, Ogilvie G, Guichon J, Gilca V, **Rosberger Z**. Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study. *BMC Public Health*. 2016 Dec 5;16(1):1223.
2. Perez S, Shapiro GK, Tatar O, Joyal-Desmarais K, **Rosberger Z**. Development and Validation of the Human Papillomavirus Attitudes and Beliefs Scale in a National Canadian Sample. *Sex Transm Dis*. 2016 Oct;43(10):626-32. doi: 10.1097/OLQ.0000000000000506.
3. Perez S, Tatar O, Ostini R, Shapiro GK, Waller J, Zimet G, **Rosberger Z**. Extending and validating a human papillomavirus (HPV) knowledge measure in a national sample of Canadian parents of boys. *Prev Med*. 2016 Oct;91:43-49. doi: 10.1016/j.ypmed.2016.07.017.
4. Jones G, Perez S, Huta V, **Rosberger Z**, Lebel S. The role of human papillomavirus (HPV)-related stigma on HPV vaccine decision-making among college males. *J Am Coll Health*. 2016 Oct;64(7):545-54. doi: 10.1080/07448481.2016.1192542.
5. Daley EM, Vamos CA, Zimet GD, **Rosberger Z**, Thompson EL, Merrell L. The Feminization of HPV: Reversing Gender Biases in US Human Papillomavirus Vaccine Policy. *Am J Public Health*. 2016 Jun;106(6):983-4. doi: 10.2105/AJPH.2016.303122. No abstract available.
6. Perez S, Fedoruk C, Shapiro GK, **Rosberger Z**. Giving Boys a Shot: The HPV Vaccine's Portrayal in Canadian Newspapers. *Health Commun*. 2016 Dec;31(12):1527-38. doi: 10.1080/10410236.2015.1089466.
7. Shapiro GK, Perez S, **Rosberger Z**. Including males in Canadian human papillomavirus vaccination programs: a policy analysis. *CMAJ*. 2016 Sep 6;188(12):881-6. doi: 10.1503/cmaj.150451. Review. No abstract available.
8. Kasting ML, Shapiro GK, **Rosberger Z**, Kahn JA, Zimet GD. Tempest in a teapot: A systematic review of HPV vaccination and risk compensation research. *Hum Vaccin Immunother*. 2016 Jun 2;12(6):1435-50. doi: 10.1080/21645515.2016.1141158.
9. Henry M, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, **Rosberger Z**, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. *Palliat Support Care*. 2016 Aug;14(4):364-75. doi: 10.1017/S1478951515001005.

Siham Sabri

1. Mariia Patyka*, Zeinab Sharifi, Kevin Petrecca, Jose Mansure, Bertrand Jean-Claude and **Siham Sabri**. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. *Oncotarget*; August 11, 2016. 7(37):60245-60269.
2. Ayman Oweida, Zeinab Sharifi**, Hani Halabi, Yaoxian Xu, **Siham Sabri** and Bassam Abdulkarim. Differential Response to Ablative Ionizing Radiation in Genetically Distinct Non-Small Cell Lung Cancer Cells. *Cancer Biology & Therapy*, 2016 Apr 2;17(4):390-9.

Veena Sangwan

1. Charles V. Rajadurai, Serhiy Havrylov, Paula P. Coelho, Colin D.H. Ratcliffe, Kossay Zaoui, Bruce H. Huang, Anie Monast, Naila Chughtai, **Veena Sangwan**, Frank B. Gertler, Peter M. Siegel, Morag Park. 5'-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion JCB 2016. DOI: 10.1083/jcb.201501003

Jan Seuntjens

1. Ola M Maria, Ahmed M Maria, Norma Ybarra, Krishinima Jeyaseelan, Sangkyu Lee, Jessica Perez, Mostafa Y Shalaby, Shirley Lehnert, Sergio Faria, Monica Serban, **Jan Seuntjens**, Issam El Naqa Mesenchymal Stem Cells Adopt Lung Cell Phenotype in Normal and Radiation-induced Lung Injury Conditions, Applied immunohistochemistry & molecular morphology: 2016 Apr; 24(4):283-95. doi: 10.1097/PAI.0000000000000180.
2. Aldelaijan S, Alzorkany F, Moftah B, Buzurovic I, **Seuntjens J**, Tomic N, Devic S. (2016) Use of a control film piece in radiochromic film dosimetry, Phys. Med. 32(1): 202-207; January, 2016.
3. Serban M., **Seuntjens J**, Roussin E, Alexander A, Tremblay JR, Wierzbicki W. (2016) Patient-specific compensation for Co-60 TBI treatments based on Monte Carlo design: A feasibility study, Phys. Med. 32(1): 67-75, January 2016.
4. Watson PG and **Seuntjens J**. (2016) Technical Note: Effect of explicit M and N-shell atomic transitions on a low-energy x-ray source, Med Phys. 43(4):1760. doi: 10.1118/1.4943954, 2016 April.
5. Piotr Pater, Gloria Backstrom Fernanda Villegas, Anders Ahnesjo, Shirin Enger, **Jan Seuntjens** and Issam El Naqa (2016) Proton and light ion RBE for the induction of initial DNA double strand breaks, Med Phys. 43(5):2131. doi: 10.1118/1.4944870, 2016 May.
6. P Papaconstadopoulos†, I R Levesque, R Maglieri, and **J Seuntjens** (2016) Direct reconstruction of the source intensity distribution of a clinical linear accelerator using a maximum likelihood expectation maximization algorithm, Physics in medicine and biology 61(3): 1078-1094; February 1, 2016.
7. P. Papaconstadopoulos†, **Jan Seuntjens** and Slobodan Devic (2016) Response to “Comment on ‘A protocol for EBT3 radiochromic film dosimetry using reflection scanning’ [Med. Phys. 41(12), 122101 (6pp.) (2014)], Med. Phys. 43(3): 1580; March 2016.
8. Slobodan Devic, Huriyyah Mohammed, Nada Tomic, Saad Aldelaijan, Francois De Blois, **Jan Seuntjens**, Shirley Lehnert, and Sergio Faria (2016) FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes, Br J Radiol 89: 20150388, March 2016.
9. Claudio Fiorino and **Jan Seuntjens** (2016) The role of medical physics in prostate cancer radiation therapy, Physica medica 32(3): 435-437.
10. Devesh Bekah†, Daniel Cooper, Konstantin Kudinov, Colin Hill, **Jan Seuntjens**, Stephen Bradforth and Jay Nadeau (2016) Synthesis and Characterization of Biologically Stable, Doped LaF3 Nanoparticles Co-Conjugated to PEG and Photosensitizers, Journal of Photochemistry and Photobiology A: Chemistry Volume 329, 1 October 2016, Pages 26–34.
11. Renaud J†, Rossomme S, Sarfehnia A, Vynckier S, Palmans H, Kacperek A, **Seuntjens J** (2016) Development and application of a water calorimeter for the absolute dosimetry of short-range particle beams, Phys Med Biol. 2016 Sep 21;61(18):6602-6619.

George Shenouda

1. Siu LL, Waldron JN, Chen BE, Winkquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, **Shenouda G**, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. *JAMA Oncol*. 2016 Dec 8. doi: 10.1001/jamaoncol.2016.4510.
2. Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Kanski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, **Shenouda G**, Matthiesen C, Le QT, Bruner D. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. *Int J Radiat Oncol Biol Phys*. 2016 Aug 12. pii: S0360-3016(16)32997-2. doi: 10.1016/j.ijrobp.2016.08.003.
3. Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, **Shenouda G**, Spencer SA, Harris J, Le QT. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. *Int J Radiat Oncol Biol Phys*. 2016 Aug 1;95(5):1346-54. doi: 10.1016/j.ijrobp.2016.03.011.
4. Faria SL, Neto OB, Cury F, **Shenouda G**, Russel R, Souhami L. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes. *Can J Urol*. 2016 Apr;23(2):8209-14.

Luis Souhami

1. Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, **Souhami L**, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efsthathiou JA. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. *Eur Urol*. 69:204-10,2016
2. Barbosa Neto O, **Souhami L**, Faria S. Hypofractionated radiation therapy for prostate cancer: The McGill University Health Centre experience. *Cancer Radiother*. 19:431-436,2015.
3. Warner A, Pickles T, Crook J, Martin AG, **Souhami L**, Catton C, Lukka H, Rodrigues G. Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. *Cureus*. 2015 Jun 11;7(6):e276. doi: 10.7759/cureus.276. e Collection 2015 Jun.
4. Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, Dreicer R, Wallace HJ 3rd, **Souhami L**, Dobelbower MC, Sandler HM, Shipley WU. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. *Int J Radiat Oncol Biol Phys*. 94:67-74, 2016.

5. Faria SL, Barbosa Neto O, Cury F, Shenouda G, Russel R, **Souhami L**. Moderate hypofractionated external beam radiotherapy for intermediate risk prostate cancer: long term outcomes. *Can J Urol* 23:8209-8214,2016.
6. Dal Pra A, **Souhami L**. Prostate cancer radiation therapy: a physician's perspective. *Phys Med* 32:438-445, 2016.
7. Eapen L, Jones E, Kassouf W, Lambert C, Morgan SC, Moussa M, Nam R, Parliament MB, Russel L, Saad F, Siemens DR, **Souhami L**, Azumacher E, Tyldesley S, Xu Y, Azieranowski I, Breau RH, Belanger E, Black P, Estey E, Bowan J, Bora B, Brundage M, Chung PWM, Fleshner N, Evans A, Bauman GS, Azawa J, Davidson C, Brimo F. Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. *Can Urol Assoc J*.10:90-94,2016.
8. Coates J, **Souhami L**, El Naqa I. Big data analytics for prostate radiotherapy. *Front Oncol*. 14:149, 2016.
9. Loblaw A, Pickles T, Crook J, Martin AG, Vigneault E, **Souhami L**, Cury F, Morris J, Catton C, Lukka H, Cheung P, Sethukavalan P, Warner A, Yang Y, Rodrigues G; Genitourinary Radiation Oncologists of Canada (GUROC). Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. *Clin Oncol (R Coll Radiol)*. 2016 Oct 22. pii: S0936-6555(16)30324-7. doi: 10.1016/j.clon.2016.10.001.
10. Shenouda G, **Souhami L**, Petrecca K, Owen S, Panet-Raymond V, Guiot MC, Corredor AG, Abdulkarim B. A Phase 2 trial of neoadjuvant temozolomide followed by hypofractionated accelerated radiation Therapy with concurrent and adjuvant temozolomide for patients with glioblastoma. *Int J Radiat Oncol Biol Phys* 2016 Nov 15. pii: S0360-3016(16)33428-9. doi: 10.1016/j.ijrobp.2016.11.006.

Barry Stein

1. Fiore JF Jr, Castelino T, Pecorelli N, Niculiseanu P, Balvardi S, Hershorn O, Liberman S, Charlebois P, **Stein B**, Carli F, Mayo N, Feldman LS. Ensuring Early Mobilization Within an Enhanced Recovery Program for Colorectal Surgery: A Randomized Controlled Trial. *Ann Surg*. 2016 Dec 16. doi: 10.1097/SLA.0000000000002114. [Epub ahead of print]
2. Pecorelli N, Hershorn O, Baldini G, Fiore JF Jr, **Stein BL**, Liberman AS, Charlebois P, Carli F, Feldman LS. Impact of adherence to care pathway interventions on recovery following bowel resection within an established enhanced recovery program. *Surg Endosc*. 2016 Aug 18. [Epub ahead of print]
3. Minnella EM, Awasthi R, Gillis C, Fiore JF Jr, Liberman AS, Charlebois P, **Stein B**, Bousquet-Dion G, Feldman LS, Carli F. Patients with poor baseline walking capacity are most likely to improve their functional status with multimodal prehabilitation. *Surgery*. 2016 Oct;160(4):1070-9. doi: 10.1016/j.surg.2016.05.036.

Khalil Sultanem

1. Roskies M, Kay-Rivest E, Mascarella MA, **Sultanem K**, Mlynarek A, Hier M. Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy. *J Otolaryngol Head Neck Surg*. 2016 Oct 10;45(1):50.
2. Wyatt G, Pugh SL, Wong RK, Sagar S, Singh AK, Koyfman SA, Nguyen Tân PF, Yom SS, Cardinale FS, **Sultanem K**, Hodson I, Kreml GA, Lukaszczyk B, Yeh AM, Berk L.

- Xerostomia health-related quality of life: NRG oncology RTOG 0537. *Qual Life Res.* 2016 Sep;25(9):2323-33.
3. Morand GB, Madana J, Da Silva SD, Roskies M, **Sultanem K**, Black MJ, Mlynarek AM, Hier MP. Survival and quality of life in oropharyngeal cancer patients treated with primary chemoradiation after salivary gland transfer. *J Laryngol Otol.* 2016 Aug;130(8):755-62
 4. Madana J, Morand GB, Alrasheed A, Gabra N, Laliberté F, Barona-Lleo L, Yolmo D, Black MJ, **Sultanem K**, Hier MP. Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma. *Head Neck.* 2016 Apr;38 Suppl 1:E1277-80.
 5. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, **Sultanem K**, Muanza T. (December 09, 2016) Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. *Cureus* 8(12): e924. doi:10.7759/cureus.924

Ivan Topisirovic

1. Hulea L, Markovic Z, **Topisirovic I**, Simmet T, Trajkovic V (2016) Biomedical potential of mTOR modulation by nanoparticles. *Trends Biotechnol.* pii: S0167-7799(16)00018-4. doi: 10.1016/j.tibtech.2016.01.005. ** (co-corresponding).
2. Gandin V, Masvidal L*, Hulea L, Gravel SP, Cargnello M, McLaughlan S, Cai Y, Morita M, Rajakumar A, Pollak M, Porco JA Jr., St-Pierre J, Pelletier J, Larsson O, **Topisirovic I**** (2016) nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related mTOR-sensitive mRNAs *Genome Research*, pii: gr.197566.115. [Epub ahead of print].
3. Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, Tenkerian C, Jean-Jean O, Stambolic V, Trost M, Larose L, Koromilas AE, Asano K, Litchfield D, Larsson O and **Topisirovic I** (2016) mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. *Nature Comm.*, 7:11127. doi: 10.1038/ncomms11127.
4. Chu J*, Cargnello M, **Topisirovic I**, Pelletier J (2016) Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer. *Trends Cell Biol.* pii: S0962-8924(16)30076-9.
5. Carbonneau M, Gagné LM, Lalonde ME, Germain MA, Motorina A, Guiot MC, Secco B, Vincent E, Tumber A, Hulea L, Bergeman J, Oppermann U, Jones R, Laplante M, **Topisirovic I**, Petrecca K, Huot ME, Mallette FA (2016) The oncometabolite 2-hydroxyglutarate activates the mTOR signaling pathway. *Nature Comm.* 7:12700. doi: 10.1038/ncomms12700 (Faculty of 1000 rated)
6. Song J, Perreault JP, **Topisirovic I**, Richard S (2016) RNA G-quadruplexes and their potential regulatory roles in translation. *Translation (Taylor & Francis)* Article: e1244031
7. St-Pierre J, **Topisirovic I**. (2016) Nucleus to Mitochondria: Lost in Transcription, Found in Translation. *Dev Cell.* 37(6):490-2.

Anna Towers

1. Boquiren, V.M., Hack, T.F., Thomas, R.L., **Towers A**, Kwan W, Tilley A, Quinlan L, Miedema B. A longitudinal analysis of chronic arm morbidity following breast cancer, *Breast Cancer Research and Treatment* (2016) 157: 413-425. doi:10.1007/s10549-016-3834-8

Michel Tremblay

1. Johns N, Stretch C, Tan BH, Solheim TS, Sørhaug S, Stephens NA, Gioulbasanis I, Skipworth RJ, Deans DA, Vigano A, Ross JA, Bathe OF, **Tremblay ML**, Kaasa S, Strasser

- F, Gagnon B, Baracos VE, Damaraju S, Fearon KC. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. *J Cachexia Sarcopenia Muscle*. 2016 Aug 5. doi: 10.1002/jcsm.12138. [Epub ahead of print]
2. Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P, Labbé DP, Bégin LR, **Tremblay ML**, Park M, Bourque G, St-Pierre J, Muller WJ, Giguère V. $ERR\alpha$ mediates metabolic adaptations driving lapatinib resistance in breast cancer. *Nat Commun*. 2016 Jul 12;7:12156. doi: 10.1038/ncomms12156.
 3. Yang T, Xie Z, Li H, Yue L, Pang Z, MacNeil AJ, **Tremblay ML**, Tang JT, Lin TJ. Protein tyrosine phosphatase 1B (PTP1B) is dispensable for IgE-mediated cutaneous reaction in vivo. *Cell Immunol*. 2016 Aug-Sep;306-307:9-16. doi: 10.1016/j.cellimm.2016.05.005.
 4. Yue L, Xie Z, Li H, Pang Z, Junkins RD, **Tremblay ML**, Chen X, Lin TJ. Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against *Pseudomonas aeruginosa* Infection. *Am J Pathol*. 2016 May;186(5):1234-44. doi: 10.1016/j.ajpath.2016.01.005.
 5. Labbé DP, Uetani N, Vinette V, Lessard L, Aubry I, Migon E, Sirois J, Haigh JJ, Bégin LR, Trotman LC, Paquet M, **Tremblay ML**. PTP1B Deficiency Enables the Ability of a High-Fat Diet to Drive the Invasive Character of PTEN-Deficient Prostate Cancers. *Cancer Res*. 2016 Jun 1;76(11):3130-5. doi: 10.1158/0008-5472.CAN-15-1501.
 6. Gungabeesoon J, **Tremblay ML**, Uetani N. Localizing PRL-2 expression and determining the effects of dietary Mg(2+) on expression levels. *Histochem Cell Biol*. 2016 Jul;146(1):99-111. doi: 10.1007/s00418-016-1427-6.
 7. Kostantin E, Hardy S, Valinsky WC, Kompatscher A, de Baaij JH, Zolotarov Y, Landry M, Uetani N, Martínez-Cruz LA, Hoenderop JG, Shrier A, **Tremblay ML**. Inhibition of PRL-2-CNNM3 Protein Complex Formation Decreases Breast Cancer Proliferation and Tumor Growth. *J Biol Chem*. 2016 May 13;291(20):10716-25. doi: 10.1074/jbc.M115.705863.
 8. Penafuerte CA, Gagnon B, Sirois J, Murphy J, MacDonald N, **Tremblay ML**. Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. *Br J Cancer*. 2016 Mar 15;114(6):680-7. doi: 10.1038/bjc.2016.3.
 9. Pike KA, **Tremblay ML**. TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. *Cytokine*. 2016 Jun;82:52-7. doi: 10.1016/j.cyto.2015.12.025.
 10. Mansour M, Nievergall E, Gegenbauer K, Llerena C, Atapattu L, Hallé M, **Tremblay ML**, Janes PW, Lackmann M. PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling. *J Cell Sci*. 2016 Jan 15;129(2):277-89. doi: 10.1242/jcs.174490.

Josie Ursini-Siegel

1. Ha JR, Siegel PM and **Ursini-Siegel J**. 2016. The tyrosine kinome dictates breast cancer heterogeneity and therapeutic responsiveness. *J. Cellular Biochemistry*, 117: 1971-1990
2. Jones LM, Broz ML, Ranger JJ, Ozcelik J, Ahn R, Zuo D, **Ursini-Siegel J**, Hallett M, Krummel D and Muller WJ. 2016. Stat3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. *Cancer Research*, 76: 416-428.
3. **Ursini-Siegel J** and Siegel PM. 2016. The influence of the pre-metastatic niche on breast cancer metastasis. *Cancer Letters*,380: 281-288. (2015 Impact Factor: 5.992)

Tsafir Vanounou

1. Levy J, Tahiri M, **Vanounou T**, Maimon G, Bergman S. Diagnostic Laparoscopy with Ultrasound Still Has a Role in the Staging of Pancreatic Cancer: A Systematic Review of the Literature. *HPB Surg.* 2016;2016:8092109. doi: 10.1155/2016/8092109. Review.2.
2. **Vanounou T**, Garfinkle R. Evaluation of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin in the Era of Value-Based Medicine. *Ann Surg Oncol.* 2016 Aug;23(8):2556-61. doi: 10.1245/s10434-016-5096-4. Review

Antonio Vigano

1. Johns N, Stretch C, Tan BH, Solheim TS, Sørhaug S, Stephens NA, Gioulbasanis I, Skipworth RJ, Deans DA, **Vigano A**, Ross JA, Bathe OF, Tremblay ML, Kaasa S, Strasser F, Gagnon B, Baracos VE, Damaraju S, Fearon KC. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. *J Cachexia Sarcopenia Muscle.* 2016 Aug 5. doi: 10.1002/jcsm.12138. [Epub ahead of print]
2. **Vigano AA**, Morais JA, Ciutto L, Rosenthal L, di Tomasso J, Khan S, Olders H, Borod M, Kilgour RD. Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. *Clin Nutr.* 2016 Sep 20. pii: S0261-5614(16)31246-8. doi: 10.1016/j.clnu.2016.09.008. [Epub ahead of print]
3. Lerner L, Tao J, Liu Q, Nicoletti R, Feng B, Krieger B, Mazsa E, Siddiquee Z, Wang R, Huang L, Shen L, Lin J, **Vigano A**, Chiu MI, Weng Z, Winston W, Weiler S, Gyuris J. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. *J Cachexia Sarcopenia Muscle.* 2016 Sep;7(4):467-82. doi: 10.1002/jcsm.12077.
4. Mamane S, Mullie L, Piazza N, Martucci G, Morais J, **Vigano A**, Levental M, Nelson K, Lange R, Afilalo J. Psoas Muscle Area and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The Montreal-Munich Study. *Can J Cardiol.* 2016 Feb;32(2):177-82. doi: 10.1016/j.cjca.2015.12.002.
5. Kilgour RD, Cardiff K, Rosenthal L, Lucar E, Trutschnigg B, **Vigano A**. Use of prediction equations to determine the accuracy of whole-body fat and fat-free mass and appendicular skeletal muscle mass measurements from a single abdominal image using computed tomography in advanced cancer patients. *Appl Physiol Nutr Metab.* 2016 Jan;41(1):70-5. doi: 10.1139/apnm-2015-0068.

Té Vuong

1. Felfoul O, Mohammadi M, Taherkhani S, de Lanauze D, Xu YZ, Loghin D, Essa S, Jancik S, Houle D, Lafleur M, Gaboury L, Tabrizian M, Kaou N, Atkin M, **Vuong T**, Batist G, Beauchemin N, Radzioch D, Martel S. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. *Nature Nanotechnology* 2016; doi:10.1038/nnano.2016.137.
2. Nout RA, Devic S, Niazi T, Wyse J, Boutros M, Pelsser V, **Vuong T**. CT-based adaptive high-dose-rate endorectal brachytherapy in the preoperative treatment of locally advanced rectal cancer: Technical and practical aspects. *Brachytherapy.* 2016 Jul-Aug; 15(4):477-84. Doi: 10.1016/j.brachy.2016.03.004. Epub 2016 Apr 16. (IF: 0.12)
3. Di Valentin T, Asmis T, Asselah J, Aubin F, Aucoin N, Berry S, Biagi J, Booth C, Burkes R, Coburn N, Colwell B, Cripps C, Dawson L, Dorreen M, Frechette D, Goel R, Gray S, Hammad N, Jonker D, Kavan P, Maroun J, Nanji S, Roberge D, Samson B, Seal M, Shabana

W, Simunovic M, Snow S, Tehfe M, Thirlwell M, Tsvetkova E, Vickers M, **Vuong T**, Goodwin R. Eastern Canadian Colorectal Cancer Consensus Conference 2013: Emerging therapies in the treatment of pancreatic, rectal and colorectal cancers. Montreal, October 17-19 2013. *Current Oncology*. 2016 Feb;23(1):52-5. (IF: 1.91)

4. Schneider J, **Vuong V**, Tomic N, Hickeson M, Lisbona R, DeBlois F, Seuntjens J, Devic S. "Decomposition of FDG-PET Based Differential Uptake Volume Histograms in Rectal Cancer Patients," *Med. Phys.* 43, 3827 (2016)

Scott Weichenthal

1. Hong KY, **Weichenthal S**, Saraswat A, King G, Brauer M, Henderson SB. Systematic identification and prioritization of communities impacted by residential woodsmoke in British Columbia, Canada. *Environmental Pollution* 2016; doi: 10.1016/j.envpol.2016.10.056.
2. Lavigne E, Gasparrini A, Stieb DM, Chen H, Yasseen AS, Crighton E, To T, **Weichenthal S**, Villeneuve P, Cakmak S, Coates F, Walker M. Maternal exposure to aeroallergens and risk of early delivery. *Epidemiol* 2016; doi: 10.1097/EDE.0000000000000573
3. Godri-Pollitt KJ, Maikawa CL, Wheeler AJ, **Weichenthal S**, Dobbin NA, Liu L, Goldberg MS. Trace metal exposure is associated with increased exhaled nitric oxide in asthmatic children. *Environ Health* 2016;15:94 DOI: 10.1186/s12940-016-0173-5.
4. Tomczak A, Miller AB, **Weichenthal S**, To T, Wall C, van Donkelaar A, Martin RV, Crouse DL, Villeneuve PJ. Long-term exposure to fine particulate matter air pollution and the risk of lung cancer among participants of the Canadian National Breast Screening Study. *Int J Cancer* 2016; 139(9):1958-66. doi: 10.1002/ijc.30255.
5. Maikawa CL, **Weichenthal S**, Wheeler AJ, Dobbin NA, Smargiassi A, Evans G, Liu L, Goldberg MS, Pollitt KJ. Particulate oxidative burden as a predictor of exhaled nitric oxide in children with asthma. *Environ Health Perspect* 2016; May 6 [Epub ahead of print]
6. Lavigne E, Yasseen AS 3rd, Stieb DM, Hystad P, van Donkelaar A, Martin RV, Brook JR, Crouse DL, Burnett RT, Chen H, **Weichenthal S**, Johnson M, Villeneuve PJ, Walker M. Ambient air pollution and adverse birth outcomes: differences by maternal comorbidities. *Environ Res* 2016; 148: 457-466.
7. Chen H, Kwong JC, Copes R, Villeneuve PJ, Goldberg MS, **Weichenthal S**, van Donkelaar A, Jerrett M, Martin RV, Brook JR, Kopp A, Burnett RT. Cohort profile: the Ontario Population Health and Environment Cohort (ONPHEC). *Int J Epidemiol* 2016;
8. Pinault L, Tjepkma M, Crouse DL, **Weichenthal S**, van Donkelaar A, Martin RV, Brauer M, Chen H, Burnett RT. Risk estimates of mortality attributed to low concentrations of ambient fine particulate matter in the Canadian community health survey cohort. *Environ Health* 2016; 15: 18.
9. **Weichenthal S**, Crouse DL, Pinault L, Godri-Pollitt K, Lavigne E, Evans G, van Donkelaar A, Martin RV, Burnett RT. Oxidative burden of fine particulate air pollution and risk of cause-specific mortality in the Canadian Census Health and Environment Cohort (CanCHEC). *Environ Res* 2016; 146: 92-99.
10. Crouse DL, Philip S, van Donkelaar A, Martin RV, Jessiman B, Peters PA, **Weichenthal S**, Brook JR, Hubbell B, Burnett RT. A new method to jointly estimate the mortality risk of long-term exposure to fine particulate matter and its components. *Sci Rep* 2016; 6: 18916.

11. Deville CL, **Weichenthal S**, Tack R, Ragettli MS, Smargiassi A, Hatzopoulou M. Investigating the use of portable air pollution sensors to capture the spatial variability of traffic-related air pollution. *Environ Sci Technol* 2016; 50: 313-320
12. **Weichenthal S**, Lavigne E, Evans G, Godri-Pollitt, Burnett RT. Ambient PM2.5 and risk of emergency room for myocardial infarction: impact of regional PM2.5 oxidative potential. *Environ Health* 2016;
13. **Weichenthal S**, Lavigne E, Evans GJ, Godri Pollitt KJ, Burnett RT. PM2.5 and emergency room visits for respiratory illness: effect modification by oxidative potential. *Am J Resp Crit Care Med* 2016;
14. **Weichenthal S**, Lavigne E, Villeneuve P, Reeves F. Airborne pollen concentrations and emergency room visits for myocardial infarction: a multi-city case-crossover study in Ontario, Canada. *Am J Epidemiol* 2016; 183: 613-62.
15. Farrell W, **Weichenthal S**, Goldberg M, Valois MF, Shekarrizfard M, Hatzopoulou M. Near roadway air pollution across a spatially extensive road and cycling network. *Environ Pollut* 2016; 212: 498-507.
16. **Weichenthal S**, Kulka R, Lavigne E, Brauer M, Stieb D, Joseph L. Biomass burning as a source of ambient fine particulate air pollution and hospital admissions for acute myocardial infarction. *Epidemiol* 2016.

Michael Witcher

1. Saad A, Bijian K, Qiu D, da Silva SD, Marques M, Chang CH, Nassour H, Ramotar D, Damaraju S, Mackey J, Bismar T, **Witcher M**, Alaoui-Jamali MA. Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2. *Scientific Reports*. 2016 Nov 7;6:36699.
2. Manteghi S, Gingras MC, Kharitidi D, Galarneau L, Yan M, Marques M, Robert F, Cencic R, Paquet M, **Witcher M**, Pelletier M and Pause A. Haploinsufficiency of the ESCRT component HD-PTP predisposes to cancer. *Cell Reports*. 2016 May 31;15(9):1893-900.
3. Kazanets A, Shorstova T, Hilmi K, Marques M, **Witcher M**. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. *BBA Reviews Cancer* 2016 Apr;1865(2):275-88.